



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07H 21/04, 21/02, C12Q 1/68, A61K 48/00</p>	A1	<p>(11) International Publication Number: WO 00/34303</p> <p>(43) International Publication Date: 15 June 2000 (15.06.00)</p>																																																						
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/US99/28965</p> <p>(22) International Filing Date: 8 December 1999 (08.12.99)</p> <p>(30) Priority Data: 09/209,668 10 December 1998 (10.12.98) US</p> <p>(71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): MONIA, Brett, P. [US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009 (US). XU, Xiaoxing, S. [CN/US]; 18 Main Street #3, Madison, NJ 07940 (US).</p> <p>(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/US99/28965</p> <p>(22) International Filing Date: 8 December 1999 (08.12.99)</p> <p>(30) Priority Data: 09/209,668 10 December 1998 (10.12.98) US</p> <p>(71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): MONIA, Brett, P. [US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009 (US). XU, Xiaoxing, S. [CN/US]; 18 Main Street #3, Madison, NJ 07940 (US).</p> <p>(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>																																																				
<p>(21) International Application Number: PCT/US99/28965</p> <p>(22) International Filing Date: 8 December 1999 (08.12.99)</p> <p>(30) Priority Data: 09/209,668 10 December 1998 (10.12.98) US</p> <p>(71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): MONIA, Brett, P. [US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009 (US). XU, Xiaoxing, S. [CN/US]; 18 Main Street #3, Madison, NJ 07940 (US).</p> <p>(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>																																																							
<p>(54) Title: METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES</p>																																																								
<table style="width: 100%; border: none;"> <tr> <td style="width: 15%;">TNFα :</td> <td style="width: 10%;">-</td> <td style="width: 10%;">+</td> <td style="width: 10%;">+</td> <td style="width: 10%;">+</td> <td style="width: 10%;">+</td> <td style="width: 10%;">+</td> <td style="width: 10%;">+</td> <td style="width: 10%;"></td> </tr> <tr> <td>Antisense Oligo:</td> <td colspan="2">None</td> <td colspan="2">C-raf</td> <td colspan="2">Control</td> <td colspan="2"></td> </tr> <tr> <td>Time:</td> <td>0</td> <td>5</td> <td>15</td> <td>5</td> <td>15</td> <td>5</td> <td>15</td> <td>Min.</td> </tr> <tr> <td>ERK Activity</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>phospho-ELK</td> </tr> <tr> <td>JNK Activity</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>phospho-C-JUN</td> </tr> <tr> <td>p38 Activity</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>phospho-ATF-2</td> </tr> </table>			TNF α :	-	+	+	+	+	+	+		Antisense Oligo:	None		C-raf		Control				Time:	0	5	15	5	15	5	15	Min.	ERK Activity								phospho-ELK	JNK Activity								phospho-C-JUN	p38 Activity								phospho-ATF-2
TNF α :	-	+	+	+	+	+	+																																																	
Antisense Oligo:	None		C-raf		Control																																																			
Time:	0	5	15	5	15	5	15	Min.																																																
ERK Activity								phospho-ELK																																																
JNK Activity								phospho-C-JUN																																																
p38 Activity								phospho-ATF-2																																																
<p>(57) Abstract</p> <p>Methods are provided for inhibiting the expression of cell adhesion molecules using inhibitors of signaling molecules involved in human TNF-α signaling. These inhibitors include monoclonal antibodies, peptide fragments, small molecule inhibitors, and, preferably, antisense oligonucleotides. Methods for treatment of diseases, particularly inflammatory and immune diseases, associated with overexpression of cell adhesion molecules are provided.</p>																																																								

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**METHODS OF MODULATING TUMOR NECROSIS FACTOR α -INDUCED
EXPRESSION OF CELL ADHESION MOLECULES**

FIELD OF THE INVENTION

5 The present invention relates to the modulation of
expression of cell adhesion molecules. In particular,
herein are provided methods of inhibiting cell adhesion
molecule gene expression through specific inhibitors
involved in TNF- α signaling. Methods are also provided for
10 treating inflammatory and immune diseases associated with
altered expression of cell adhesion molecules.

BACKGROUND OF THE INVENTION

Cytokines represent a diverse group of regulatory
proteins with numerous biological functions including cell
15 differentiation, cell growth, and cytotoxicity. Inflammatory
cytokines such as Tumor Necrosis Factor alpha and (TNF-
 α) and IL-1 (interleukin-1) have been shown to play pivotal
roles in immune and inflammatory responses (McIntyre, T.M.,
et al., Thromb. Haemos. 1997, 78, 302-305). One of the
20 most important effector functions of these cytokines is
their ability to induce profound changes in the vascular
endothelium (Introna, M. and Mantovani, A., Art. Thromb.
and Vasc. Biol. 1997, 17, 423-428). Central to the process
of inflammation is the induction of cell adhesion molecules
25 on the endothelial cell surface, contributing significantly
to the adherence and recruitment of circulating leukocytes
to inflammatory sites. Upon exposure to TNF- α or IL-1,
which are produced in response to injury or infection,
cytokine receptors on endothelial cells activate a variety
30 of intracellular signaling molecules. These signaling
events result in the activation of specific transcription
factors such as NF- κ B and upregulate the expression of E-
selectin, ICAM-1, VCAM-1, and other cell adhesion molecules
(McIntyre, T.M., et al., Thromb. Haemos. 1997, 78, 302-305;
35 Introna, M. and Mantovani, A., Art. Thromb. and Vasc. Biol.

-2-

1997, 17, 423-428; Mantovani, A., et al., *Thromb. Haemos.* 1997, 78, 406-414). E-selectin has been shown to mediate the initial attachment and rolling of leukocytes along the vessel wall, whereas ICAM-1 and VCAM-1 are involved in the firm adhesion of leukocytes to the vessel wall and their transmigration through the vessel wall. E-selectin is rapidly and transiently induced by cytokines with peak expression occurring approximately 4-6 hours after exposure and returning to basal levels approximately 24 hours post exposure. In contrast, induction of ICAM-1 and VCAM-1 by cytokines is slower and persists for 24 hours or longer (Mantovani, A., et al., *Thromb. Haemos.* 1997, 78, 406-414; Dunon, D., et al., *Curr. Opin. Cell Bio.* 1996, 8, 714-723; Bischoff, J., *Cell Adhes. and Angiog.*, 1997, 99, 373-376).

Responses to TNF- α are mediated through interactions with two distinct membrane receptors, termed TNFRI (TNF- α receptor I) and TNFRII (TNF- α receptor II). Two distinct families of adaptor proteins associated with TNF- α receptors have been identified. The death domain-containing proteins (e.g., TRADD) appear to couple the receptors to programmed cell death (Fiers, W., et al., *J. Inflam.*, 1996, 47, 67-75; Wallach, D., et al., *FEBS Lett.*, 1997, 410, 96-106; Hsu, H., et al., *Cell*, 1996, 84, 299-308), whereas the TRAF (TNF receptor associated factor) domain-containing proteins link the receptors to activation of specific transcription factors (Hsu, H., et al., *Cell*, 1996, 84, 299-308; Baeuerle, P.A., *Curr. Biol.*, 1998, 8, R19-R22). Among the six members of the TRAF family that have been identified so far, TRAF2 has been reported to be important for TNF- α -mediated activation of JNK (c-Jun N-terminal kinase), as well as two major transcription factors, NF- κ B (nuclear factor- κ B) and AP-1 (activator protein 1) (Hsu, H., et al., *Cell*, 1996, 84, 299-308; Baeuerle, P.A., *Curr. Biol.*, 1998, 8, R19-R22; Natoli, G., et al., *J. Biol. Chem.*, 1997, 272, 26079-26082; Liu, Z.G.,

-3-

et al., Cell, 1996, 87, 565-576; Song, H.Y., et al., Proc. Natl. Acad. Sci. USA, 1997, 94, 9792-9796). Both transcription factors play pivotal roles in the regulation of multiple genes including those involved in immune and inflammatory responses. AP-1 is activated by various MAPKs (mitogen-activated protein kinase) including ERK (extracellular-signal-regulated kinase), JNK and p38 MAPK (Fiers, W., et al., J. Inflam., 1996, 47, 67-75; Eder, J., TIPS, 1997, 18, 319-322). NF-kB is constitutively present in the cytosol of endothelial cells and kept inactive by association with inhibitory IkB family proteins. Upon exposure to TNF- α , IKK (IkB kinase) phosphorylates IkB and initiates its ubiquitination and subsequent degradation. The released NF-kB translocates to the nucleus and participates in transcriptional activation (Collins, T., et al., FASEB J., 1995, 9, 899-909; Stancovski, I., and Baltimore, D., Cell, 1997, 91, 299-302).

Other signaling molecules, including MEKK1, pp90rsk (ribosomal S6 protein kinase), *ras*, and *raf*, have been implicated in the activation of NF-kB (Schulze-Osthoff, K., et al., Immunobiol., 1997, 198, 35-49). *ras* family members (Ha-*ras*, Ki-*ras*, N-*ras*) are GTP-binding proteins that act as major mediators in the regulation of cell proliferation and differentiation in response to a variety of extracellular stimuli including TNF- α (Bos, J.L., Biochem. Biophys. Acta, 1997, 1333, M19-M31). *ras* proteins have been shown to activate both the *raf*/MEK/ERK pathway as well as MEKK/JNKK/JNK pathway (Bos, J.L., Biochem. Biophys. Acta, 1997, 1333, M19-M31; Marais, R., and Marshall, C.J., Cancer Surveys, 1996, 27, 101-125; Adler, V., et al., J. Biol. Chem., 1996, 271, 23304-23309; Faris, M., et al., J. Biol. Chem., 1996, 271, 27366-27373; Terada, K., et al., J. Biol. Chem., 1997, 272, 4544-4548). *raf* family members (A-, B-, *c-raf*) are serine/threonine protein kinases that transmit signals from cell surface receptors to a variety

-4-

of intracellular effectors including the MAPK pathways (Marais, R., and Marshall, C.J., *Cancer Surveys*, 1996, 27, 101-125; Daum, G., et al., *TIBS*, 1994, 19, 474-480). Besides *ras*, a variety of protein kinases including Src family kinases and PKC (protein kinase C) can potentiate *raf* activity (Marais, R., et al., *J. Biol. Chem.*, 1997, 272, 4378-4383; Ueffing, M., et al., *Oncogene*, 1997, 15, 2921-2927). The major downstream effectors of *raf* are MEK/MKK1 (MAP kinase kinase 1) and MEK/MKK2 (MAP kinase kinase 2) which in turn phosphorylate and activate ERK1/2, and ultimately activate specific transcription factors (Marais, R., and Marshall, C.J., *Cancer Surveys*, 1996, 27, 101-125; Daum, G., et al., *TIBS*, 1994, 19, 474-480). Both *ras* and *raf* had been suggested to participate in the activation of NF- κ B transcription factors (Schulze-Osthoff, K., et al., *Immunobiol.*, 1997, 198, 35-49; Folgueira, L., et al., *J. Virol.*, 1996, 70, 2332-2338; Koong, A.C., et al., *Cancer Res.*, 1994, 54, 5273-5279; Bertrand, F., et al., *J. Biol. Chem.*, 1995, 270, 24435-24441; Kanno, T., and Siebenlist, U., *J. Immunol.*, 1996, 157, 5277-5283).

In many human diseases with an inflammatory component, the normal, homeostatic mechanisms which attenuate the inflammatory responses are defective, resulting in damage and destruction of normal tissue. For example, VCAM-1 may play a role in the metastasis of melanoma, and possibly other cancers. In addition, data have demonstrated that ICAM-1 is the cellular receptor for the major serotype of rhinovirus, which account for greater than 50% of common colds. (Staunton, et al., *Cell*, 1989, 56, 849-853; Greve et al., *Cell*, 1989, 56, 839-847).

Expression of ICAM-1 has also been associated with a variety of inflammatory skin disorders such as allergic contact dermatitis, fixed drug eruption, lichen planus, and psoriasis (Ho, et al., *J. Am. Acad. Dermatol.*, 1990, 22, 64-68; Griffiths and Nickoloff, *Am. J. Pathology*, 1989,

-5-

135, 1045-1053; Lisby, et al., Br. J. Dermatol., 1989, 120, 479-484; Shiohara, et al., Arch. Dermatol., 1989, 125, 1371-1376). In addition, ICAM-1 expression has been detected in the synovium of patients with rheumatoid
5 arthritis (Hale, et al., Arth. Rheum., 1989, 32, 22-30), pancreatic B-cells in diabetes (Campbell, et al., Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 4282-4286), thyroid follicular cells in patients with Graves' disease (Weetman, et al., J. Endocrinol., 1989, 122, 185-191), and with renal
10 and liver allograft rejection (Faull and Russ, Transplantation, 1989, 48, 226-230; Adams, et al., Lancet, 1989, 2, 1122-1125).

Inhibitors of ICAM-1, VCAM-1 and ELAM-1 expression would provide a novel therapeutic class of anti-
15 inflammatory agents with activity towards a variety of inflammatory diseases or diseases with an inflammatory component such as asthma, rheumatoid arthritis, allograft rejections, inflammatory bowel disease, various dermatological conditions, and psoriasis. In addition,
20 inhibitors of ICAM-1, VCAM-1, and ELAM-1 may also be effective in the treatment of colds due to rhinovirus infection, AIDS, Kaposi's sarcoma and some cancers and their metastasis. The use of neutralizing monoclonal antibodies against ICAM-1 in animal models provide evidence
25 that such inhibitors if identified would have therapeutic benefit for asthma (Wegner, et al., Science, 1990, 247, 456-459), renal allografts (Cosimi, et al., J. Immunol., 1990, 144, 4604-4612), and cardiac allografts (Isobe, et al., Science, 1992, 255, 1125-1127). The use of a soluble
30 form of ICAM-1 molecule was also effective in preventing rhinovirus infection of cells in culture (Marlin, et al., Nature, 1990, 344, 70-72).

Current agents which affect intercellular adhesion molecules include synthetic peptides, monoclonal
35 antibodies, soluble forms of the adhesion molecules, and

-6-

antisense oligonucleotides. Antisense oligonucleotides to cell adhesion molecules are disclosed in US Patent Nos. 5,514,788 and 5,591,623, herein incorporated by reference. These have been directed against a single cell adhesion molecule. Additional agents are desired. Furthermore, a broader approach, targeting several adhesion molecules with a single agent may have several advantages, including economies of scale, broad spectrum utility, etc. Thus, an approach to target a molecule in the TNF- α signaling pathway may be a useful therapeutic treatment, providing a means to regulate multiple cell adhesion molecules with a single agent.

Inhibitors of molecules in TNF- α mediated signaling have been used to study the signal transduction pathways and suggest utility in the design of pharmacological agents. Inhibitors that have been used include DMSO (Essani, N.A., et al., Shock, 1997, 7, 90-96) against NF- κ B, protein tyrosine kinase inhibitors (Adamson, P., et al., Cell Adhes. Commun., 1996, 3, 511-525; Pai, R., et al., J. Immunol., 1996, 156, 2571-2579), protein tyrosine kinase C inhibitors (Ballestas, M.E. and Benveniste, E.N., Glia, 1995, 14, 267-278), ubiquitin ligase inhibitors (Yaron, A., et al., EMBO J., 1997, 16, 6486-6494), and phospholipase A2 inhibitors (Thommesen, L., et al., J. Immunol., 1998, 161, 3421-3430). In addition, drugs that elevate cyclic AMP have been found to inhibit ELAM-1 and VCAM-1 (Pober, J.S., et al., J. Immunol., 1993, 150, 5114-5123).

Antisense oligonucleotides to *c-raf*, *Ha-ras* and *JNK2* are known, but have not previously been shown to inhibit cell adhesion molecule expression. The relationship between these TNF- α signaling molecules and cell adhesion molecule expression has not been fully delineated. *c-raf* antisense oligonucleotides are disclosed in US Patent Nos. 5,563,255 and 5,656,612, herein incorporated by reference. *Ha-ras* antisense oligonucleotide are disclosed in US Patent

-7-

Nos. 5,576,208 and 5,582,986, herein incorporated by reference. JNK2 antisense oligonucleotides are disclosed by Bost, F., et al. (J. Biol. Chem. 1997, 272, 33422-33429). Inhibitors of the TNF- α signaling molecules, *c-raf*, Ha-ras and JNK2 have not been used to modulate expression of cell adhesion molecules and represent a novel approach.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a Western blot showing a time-course of the effects of *c-raf* antisense oligonucleotides on *c-raf* and *a-raf* protein levels.

FIG. 2 is a Western blot showing a time-course of the effects of Ha-ras antisense oligonucleotides on Ha-ras and Ki-ras protein levels.

FIG. 3 is a Western blot showing the effects of *c-raf* antisense oligonucleotides on TNF- α mediated ERK, JNK and p38 kinase activities. Phospho-substrate-specific antibodies were used to analyze kinase activities.

FIG. 4 is Northern blot showing the effects of JNK1 and JNK2 antisense oligonucleotides on TNF- α mediated JNK1 and JNK2 mRNA expression.

FIG. 5 is a Western blot showing the effects of JNK1 and JNK2 antisense oligonucleotides on TNF- α mediated JNK1 and JNK2 kinase activity. Phospho-substrate-specific antibodies were used to analyze kinase activities.

BRIEF DESCRIPTION OF THE INVENTION

The present invention describes a method of modulating cell adhesion molecule expression within a cell comprising treating said cell with a specific inhibitor of one of the Tumor Necrosis Factor alpha (TNF- α) signaling molecules, Ha-ras, *c-raf* or JNK2. In one embodiment, the specific inhibitor is an antisense oligonucleotide capable of hybridizing to Ha-ras, *c-raf* or JNK2. Also provided are methods of treating an inflammatory or immune disease or

-8-

condition associated with altered expression of a cell adhesion molecule comprising administering a specific inhibitor of one of the TNF- α signaling molecules, Ha-ras, c-raf or JNK2.

5 DETAILED DESCRIPTION OF THE INVENTION

The present invention employs specific inhibitors of Ha-ras, c-raf and JNK2, members of the TNF- α signaling pathway, to modulate cell adhesion molecule expression. These inhibitors can include monoclonal antibodies, peptide
10 fragments, small molecule inhibitors and antisense compounds. In a preferred embodiment, antisense compounds, particularly oligonucleotides, are used to modulate the function of nucleic acid molecules encoding Ha-ras, c-raf or JNK2, modulating the amount of protein produced and
15 ultimately modulating the expression of cell adhesion molecules. This is accomplished by providing oligonucleotides which specifically hybridize with nucleic acids, preferably mRNA, encoding Ha-ras, c-raf or JNK2.

This relationship between an antisense compound such
20 as an oligonucleotide and its complementary nucleic acid target, to which it hybridizes, is commonly referred to as "antisense". "Targeting" an oligonucleotide to a chosen nucleic acid target, in the context of this invention, is a multistep process. The process usually begins with
25 identifying a nucleic acid sequence whose function is to be modulated. This may be, as examples, a cellular gene (or mRNA made from the gene) whose expression is associated with a particular disease state, or a foreign nucleic acid from an infectious agent. In the present invention, the
30 targets are nucleic acids encoding Ha-ras, c-raf or JNK2; in other words, a gene encoding Ha-ras, c-raf or JNK2, or mRNA expressed from the Ha-ras, c-raf or JNK2 gene. mRNA which encodes Ha-ras, c-raf or JNK2 is presently the preferred target. The targeting process also includes

-9-

determination of a site or sites within the nucleic acid sequence for the antisense interaction to occur such that modulation of gene expression will result.

In accordance with this invention, persons of ordinary skill in the art will understand that messenger RNA includes not only the information to encode a protein using the three letter genetic code, but also associated ribonucleotides which form a region known to such persons as the 5'-untranslated region, the 3'-untranslated region, the 5' cap region and intron/exon junction ribonucleotides. Thus, oligonucleotides may be formulated in accordance with this invention which are targeted wholly or in part to these associated ribonucleotides as well as to the informational ribonucleotides. The oligonucleotide may therefore be specifically hybridizable with a transcription initiation site region, a translation initiation codon region, a 5' cap region, an intron/exon junction, coding sequences, a translation termination codon region or sequences in the 5'- or 3'-untranslated region. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon." A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular

-10-

set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding Ha-ras, c-raf or JNK2, regardless of the sequence(s) of such codons. It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, *i.e.*, 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region," "AUG region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (*i.e.*, 5' or 3') from a translation initiation codon. This region is a preferred target region. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (*i.e.*, 5' or 3') from a translation termination codon. This region is a preferred target region. The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other preferred target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or

-11-

corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a pre-mRNA transcript to yield one or more mature mRNA. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, *i.e.*, exon-exon or intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. Targeting particular exons in alternatively spliced mRNAs may also be preferred. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once the target site or sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, *i.e.*, hybridize sufficiently well and with sufficient specificity, to give the desired modulation.

"Hybridization", in the context of this invention, means hydrogen bonding, also known as Watson-Crick base pairing, between complementary bases, usually on opposite nucleic acid strands or two regions of a nucleic acid strand. Guanine and cytosine are examples of complementary bases which are known to form three hydrogen bonds between

-12-

them. Adenine and thymine are examples of complementary bases which form two hydrogen bonds between them.

"Specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide.

It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, *i.e.*, under physiological conditions in the case of *in vivo* assays or therapeutic treatment and, in the case of *in vitro* assays, under conditions in which the assays are conducted.

Hybridization of antisense oligonucleotides with mRNA interferes with one or more of the normal functions of mRNA. The functions of mRNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in by the RNA. Binding of specific protein(s) to the RNA may also be interfered with by antisense oligonucleotide hybridization to the RNA.

The overall effect of interference with mRNA function is modulation of expression of *c-raf*, *Ha-ras* or *JNK2* and, in the context of this invention, ultimately modulation of cellular adhesion molecule expression. In the context of this invention "modulation" means either inhibition or

-13-

stimulation; i.e., either a decrease or increase in expression. This modulation can be measured in ways which are routine in the art, for example by Northern blot assay of mRNA expression, or reverse transcriptase PCR, as taught
5 in the examples of the instant application or by Western blot or ELISA assay of protein expression, or by an immunoprecipitation assay of protein expression. Effects on cell proliferation or tumor cell growth can also be measured, as taught in the examples of the instant
10 application. Inhibition is presently preferred.

The oligonucleotides of this invention can be used in diagnostics, therapeutics, prophylaxis, and as research reagents and in kits. Since the oligonucleotides of this invention hybridize to nucleic acids encoding Ha-ras, c-raf
15 or JNK2, sandwich, colorimetric and other assays can easily be constructed to exploit this fact. Provision of means for detecting hybridization of oligonucleotide with the Ha-ras, c-raf or JNK2 gene or mRNA can routinely be accomplished. Such provision may include enzyme
20 conjugation, radiolabelling or any other suitable detection systems. Kits for detecting the presence or absence of Ha-ras, c-raf or JNK2 may also be prepared.

The present invention is also suitable for diagnosing abnormal inflammatory states in tissue or other samples
25 from patients suspected of having an inflammatory disease such as rheumatoid arthritis. The ability of the oligonucleotides of the present invention to inhibit inflammatory processes may be employed to diagnose such states. A number of assays may be formulated employing the
30 present invention, which assays will commonly comprise contacting a tissue sample with an oligonucleotide of the invention under conditions selected to permit detection and, usually, quantitation of such inhibition. In the context of this invention, to "contact" tissues or cells
35 with an oligonucleotide or oligonucleotides means to add

-14-

the oligonucleotide(s), usually in a liquid carrier, to a cell suspension or tissue sample, either *in vitro* or *ex vivo*, or to administer the oligonucleotide(s) to cells or tissues within an animal.

5 The oligonucleotides of this invention may also be used for research purposes. For example, the function of a specific gene product in a signaling pathway may be investigated using specific oligonucleotides. Thus, the specific hybridization exhibited by the oligonucleotides
10 may be used for assays, purifications, cellular product preparations and in other methodologies which may be appreciated by persons of ordinary skill in the art.

 In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of
15 ribonucleic acid or deoxyribonucleic acid. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent intersugar (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified
20 or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced binding to target and increased stability in the presence of nucleases.

25 The antisense compounds in accordance with this invention preferably comprise from about 5 to about 50 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30 nucleobases (*i.e.* from about 8 to about 30 linked
30 nucleosides). As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further
35 include a phosphate group covalently linked to the sugar

-15-

portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs

-16-

of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the
5 preparation of the above phosphorus-containing linkages
include, but are not limited to, U.S.: 3,687,808;
4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897;
5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131;
5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677;
10 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111;
5,563,253; 5,571,799; 5,587,361; and 5,625,050.

Preferred modified oligonucleotide backbones that do
not include a phosphorus atom therein have backbones that
are formed by short chain alkyl or cycloalkyl
15 internucleoside linkages, mixed heteroatom and alkyl or
cycloalkyl internucleoside linkages, or one or more short
chain heteroatomic or heterocyclic internucleoside
linkages. These include those having morpholino linkages
(formed in part from the sugar portion of a nucleoside);
20 siloxane backbones; sulfide, sulfoxide and sulfone
backbones; formacetyl and thioformacetyl backbones;
methylene formacetyl and thioformacetyl backbones; alkene
containing backbones; sulfamate backbones; methyleneimino
and methylenehydrazino backbones; sulfonate and sulfonamide
25 backbones; amide backbones; and others having mixed N, O, S
and CH₂ component parts.

Representative United States patents that teach the
preparation of the above oligonucleosides include, but are
not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444;
30 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;
5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677;
5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;
5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;
5,663,312; 5,633,360; 5,677,437; and 5,677,439.

-17-

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, *i.e.*, the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262. Further teaching of PNA compounds can be found in Nielsen et al. (Science, 1991, 254, 1497-1500).

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$ [known as a methylene (methylimino) or MMI backbone], $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$ and $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$ [wherein the native phosphodiester backbone is represented as $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl, O-alkyl-O-alkyl, O-, S-, or N-alkenyl, or O-, S- or N-alkynyl, wherein the alkyl, alkenyl and

-18-

alkynyl may be substituted or unsubstituted C_1 to C_{10} alkyl or C_2 to C_{10} alkenyl and alkynyl. Particularly preferred are $O[(CH_2)_nO]_mCH_3$, $O(CH_2)_nOCH_3$, $O(CH_2)_2ON(CH_3)_2$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, $O(CH_2)_nONH_2$, and $O(CH_2)_nON[(CH_2)_nCH_3]_2$, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH_3 , OCN, Cl, Br, CN, CF_3 , OCF_3 , $SOCH_3$, SO_2CH_3 , ONO_2 , NO_2 , N_3 , NH_2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O- $CH_2CH_2OCH_3$, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a $O(CH_2)_2ON(CH_3)_2$ group, also known as 2'-DMAOE, as described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O- CH_3), 2'-aminopropoxy (2'-O $CH_2CH_2CH_2NH_2$) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugars structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811;

-19-

5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,0531
5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or
5 substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine
10 (5-me-C or m5c), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine,
15 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils
20 and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in the Concise
25 Encyclopedia Of Polymer Science And Engineering, 1990, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, those disclosed by Englisch et al. (Angewandte Chemie, International Edition, 1991, 30, 613-722), and those disclosed by Sanghvi, Y.S., Chapter 15, Antisense Research
30 and Applications, 1993, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-
35 2, N-6 and O-6 substituted purines, including 2-

-20-

aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds.,

5 Antisense Research and Applications, 1993, CRC Press, Boca Raton, pages 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the
10 preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908;
15 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which
20 enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1059), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci.,
25 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic
30 chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., dihexadecyl-rac-glycerol or triethylammonium 1,2-di-O-
35 hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.,

-21-

Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid
5 (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta., 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937).

10 Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802;
15 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506;
20 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

25 The present invention also includes oligonucleotides which are chimeric oligonucleotides. "Chimeric" oligonucleotides or "chimeras," in the context of this invention, are oligonucleotides which contain two or more chemically distinct regions, each made up of at least one
30 nucleotide. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An
35 additional region of the oligonucleotide may serve as a

-22-

substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in
5 cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense inhibition of gene expression. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. This RNase H-
10 mediated cleavage of the RNA target is distinct from the use of ribozymes to cleave nucleic acids. Ribozymes are not comprehended by the present invention.

Examples of chimeric oligonucleotides include but are not limited to "gapmers," in which three distinct regions
15 are present, normally with a central region flanked by two regions which are chemically equivalent to each other but distinct from the gap. A preferred example of a gapmer is an oligonucleotide in which a central portion (the "gap") of the oligonucleotide serves as a substrate for RNase H
20 and is preferably composed of 2'-deoxynucleotides, while the flanking portions (the 5' and 3' "wings") are modified to have greater affinity for the target RNA molecule but are unable to support nuclease activity (e.g., fluoro- or 2'-O-methoxyethyl- substituted). Chimeric oligonucleotides
25 are not limited to those with modifications on the sugar, but may also include oligonucleosides or oligonucleotides with modified backbones, e.g., with regions of phosphorothioate (P=S) and phosphodiester (P=O) backbone linkages or with regions of MMI and P=S backbone linkages.
30 Other chimeras include "wingmers," also known in the art as "hemimers," that is, oligonucleotides with two distinct regions. In a preferred example of a wingmer, the 5' portion of the oligonucleotide serves as a substrate for RNase H and is preferably composed of 2'-deoxynucleotides,
35 whereas the 3' portion is modified in such a fashion so as

-23-

to have greater affinity for the target RNA molecule but is unable to support nuclease activity (e.g., 2'-fluoro- or 2'-O-methoxyethyl- substituted), or vice-versa. In one embodiment, the oligonucleotides of the present invention contain a 2'-O-methoxyethyl (2'-O-CH₂CH₂OCH₃) modification on the sugar moiety of at least one nucleotide. This modification has been shown to increase both affinity of the oligonucleotide for its target and nuclease resistance of the oligonucleotide. According to the invention, one, a plurality, or all of the nucleotide subunits of the oligonucleotides of the invention may bear a 2'-O-methoxyethyl (-O-CH₂CH₂OCH₃) modification. Oligonucleotides comprising a plurality of nucleotide subunits having a 2'-O-methoxyethyl modification can have such a modification on any of the nucleotide subunits within the oligonucleotide, and may be chimeric oligonucleotides. Aside from or in addition to 2'-O-methoxyethyl modifications, oligonucleotides containing other modifications which enhance antisense efficacy, potency or target affinity are also preferred. Chimeric oligonucleotides comprising one or more such modifications are presently preferred.

The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of the routineer. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and 2'-alkoxy or 2'-alkoxyalkoxy derivatives, including 2'-O-methoxyethyl oligonucleotides (Martin, P., Helv. Chim. Acta, 1995, 78, 486-504). It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as

-24-

biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling, VA) to synthesize fluorescently labeled, biotinylated or other conjugated oligonucleotides.

5 The antisense compounds of the present invention include bioequivalent compounds, including pharmaceutically acceptable salts and prodrugs. This is intended to encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon
10 administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of the nucleic acids of the invention and
15 prodrugs of such nucleic acids. "Pharmaceutically acceptable salts" are physiologically and pharmaceutically acceptable salts of the nucleic acids of the invention: *i.e.*, salts that retain the desired biological activity of the parent compound and do not impart undesired
20 toxicological effects thereto (see, for example, Berge *et al.*, "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19).

For oligonucleotides, examples of pharmaceutically acceptable salts include but are not limited to (a) salts
25 formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, *etc.*; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the
30 like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid,
35 naphthalenesulfonic acid, methanesulfonic acid, p-

-25-

toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

5 The oligonucleotides of the invention may additionally or alternatively be prepared to be delivered in a "prodrug" form. The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (*i.e.*, drug) within the body or cells
10 thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO
15 93/24510 to Gosselin et al., published December 9, 1993.

For therapeutic or prophylactic treatment, oligonucleotides are administered in accordance with this invention. Oligonucleotide compounds of the invention may be formulated in a pharmaceutical composition, which may
20 include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, surface active agents, neutral or cationic lipids, lipid complexes, liposomes, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients and the
25 like in addition to the oligonucleotide. Such compositions and formulations are comprehended by the present invention.

Pharmaceutical compositions comprising the oligonucleotides of the present invention may include penetration enhancers in order to enhance the alimentary
30 delivery of the oligonucleotides. Penetration enhancers may be classified as belonging to one of five broad categories, *i.e.*, fatty acids, bile salts, chelating agents, surfactants and non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, 8,
35 91-192; Muranishi, Critical Reviews in Therapeutic Drug

-26-

Carrier Systems, 1990, 7, 1-33). One or more penetration enhancers from one or more of these broad categories may be included.

Various fatty acids and their derivatives which act as
5 penetration enhancers include, for example, oleic acid, lauric acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, recinleate, monoolein (a.k.a. 1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid,
10 glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, mono- and di-glycerides and physiologically acceptable salts thereof (*i.e.*, oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., Critical Reviews in
15 Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1; El-Hariri et al., J. Pharm. Pharmacol., 1992 44, 651-654).

The physiological roles of bile include the
20 facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY, 1996, pages 934-935). Various natural bile salts, and their
25 synthetic derivatives, act as penetration enhancers. Thus, the term "bile salt" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives.

Complex formulations comprising one or more
30 penetration enhancers may be used. For example, bile salts may be used in combination with fatty acids to make complex formulations.

Chelating agents include, but are not limited to, disodium ethylenediaminetetraacetate (EDTA), citric acid,
35 salicylates (e.g., sodium salicylate, 5-methoxysalicylate

-27-

and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and *N*-amino acyl derivatives of beta-diketones (enamines) [Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51). Chelating agents have the added advantage of also serving as DNase inhibitors.

Surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and perfluorochemical emulsions, such as FC-43 (Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252-257).

Non-surfactants include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626).

As used herein, "carrier compound" refers to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a

-28-

common receptor. In contrast to a carrier compound, a "pharmaceutically acceptable carrier" (excipient) is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The pharmaceutically acceptable carrier may be liquid or solid and is selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrates (e.g., starch, sodium starch glycolate, etc.); or wetting agents (e.g., sodium lauryl sulphate, etc.). Sustained release oral delivery systems and/or enteric coatings for orally administered dosage forms are described in U.S. Patents Nos. 4,704,295; 4,556,552; 4,309,406; and 4,309,404.

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional compatible pharmaceutically-active materials such as, e.g., antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage

-29-

forms of the composition of present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the invention.

Regardless of the method by which the oligonucleotides of the invention are introduced into a patient, colloidal dispersion systems may be used as delivery vehicles to enhance the *in vivo* stability of the oligonucleotides and/or to target the oligonucleotides to a particular organ, tissue or cell type. Colloidal dispersion systems include, but are not limited to, macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and lipid:oligonucleotide complexes of uncharacterized structure. A preferred colloidal dispersion system is a plurality of liposomes. Liposomes are microscopic spheres having an aqueous core surrounded by one or more outer layers made up of lipids arranged in a bilayer configuration (see, generally, Chonn et al., Current Op. Biotech., 1995, 6, 698-708).

The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, epidermal, and transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, pulmonary administration, e.g., by inhalation or insufflation, or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

-30-

Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or
5 oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-
10 aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers,
15 diluents and other suitable additives. In some cases it may be more effective to treat a patient with an oligonucleotide of the invention in conjunction with other traditional therapeutic modalities in order to increase the efficacy of a treatment regimen. In the context of the
20 invention, the term "treatment regimen" is meant to encompass therapeutic, palliative and prophylactic modalities. For example, a patient may be treated with conventional chemotherapeutic agents, particularly those used for tumor and cancer treatment. Examples of such
25 chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin
30 D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-
35 mercaptopurine, 6-thioguanine, cytarabine (CA), 5-

-31-

azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide, trimetrexate, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed., 1987, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide).

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective *in vitro* and in *in vivo* animal models. In general, dosage is from 0.01 μ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or

-32-

tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 μg to 100 g per kg of body weight, once or more daily, to once every 20 years.

Thus, in the context of this invention, by "therapeutically effective amount" is meant the amount of the compound which is required to have a therapeutic effect on the treated individual. This amount, which will be apparent to the skilled artisan, will depend upon the age and weight of the individual, the type of disease to be treated, perhaps even the gender of the individual, and other factors which are routinely taken into consideration when designing a drug treatment. A therapeutic effect is assessed in the individual by measuring the effect of the compound on the disease state in the animal. For example, if the disease to be treated is cancer, therapeutic effects are assessed by measuring the rate of growth or the size of the tumor, or by measuring the production of compounds such as cytokines, production of which is an indication of the progress or regression of the tumor.

The following examples illustrate the present invention and are not intended to limit the same.

EXAMPLES

EXAMPLE 1: Synthesis of Oligonucleotides

Unmodified oligodeoxynucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine. β -cyanoethyldiisopropyl-phosphoramidites are purchased from Applied Biosystems (Foster City, CA). For phosphorothioate oligonucleotides, the standard oxidation bottle was replaced by a 0.2 M solution of ^3H -1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation

-33-

cycle wait step was increased to 68 seconds and was followed by the capping step. Cytosines may be 5-methyl cytosines. (5-methyl deoxycytidine phosphoramidites available from Glen Research, Sterling, VA or Amersham Pharmacia Biotech, Piscataway, NJ)

2'-methoxy oligonucleotides are synthesized using 2'-methoxy β -cyanoethyldiisopropyl-phosphoramidites (Chemgenes, Needham, MA) and the standard cycle for unmodified oligonucleotides, except the wait step after pulse delivery of tetrazole and base is increased to 360 seconds. Other 2'-alkoxy oligonucleotides are synthesized by a modification of this method, using appropriate 2'-modified amidites such as those available from Glen Research, Inc., Sterling, VA.

2'-fluoro oligonucleotides are synthesized as described in Kawasaki et al. (J. Med. Chem., 1993, 36, 831-841). Briefly, the protected nucleoside N⁶-benzoyl-2'-deoxy-2'-fluoroadenosine is synthesized utilizing commercially available 9- β -D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'- α -fluoro atom is introduced by a S_N2-displacement of a 2'- β -O-triflyl group. Thus N⁶-benzoyl-9- β -D-arabinofuranosyladenine is selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N⁶-benzoyl groups is accomplished using standard methodologies and standard methods are used to obtain the 5'-dimethoxytrityl- (DMT) and 5'-DMT-3'-phosphoramidite intermediates.

The synthesis of 2'-deoxy-2'-fluoroguanosine is accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9- β -D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group is followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine.

-34-

Selective O-deacylation and triflation is followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies are used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

5 Synthesis of 2'-deoxy-2'-fluorouridine is accomplished by the modification of a known procedure in which 2, 2'-anhydro-1- β -D-arabinofuranosyluracil is treated with 70% hydrogen fluoride-pyridine. Standard procedures are used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

10 2'-deoxy-2'-fluorocytidine is synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N⁴-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures are used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

15 2'-(2-methoxyethyl)-modified amidites were synthesized according to Martin, P. (Helv. Chim. Acta, 1995, 78, 486-506). For ease of synthesis, the last nucleotide may be a deoxynucleotide. 2'-O-CH₂CH₂OCH₃-cytosines may be 5-methyl cytosines.

20 **Synthesis of 5-Methyl cytosine monomers:**

2,2'-Anhydro[1-(β -D-arabinofuranosyl)-5-methyluridine]:

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate
25 (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup
30 was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum
35 was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to

-35-

give a solid which was crushed to a light tan powder (57 g, 85% crude yield). The material was used as is for further reactions.

2'-O-Methoxyethyl-5-methyluridine:

5 2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the
10 solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel
15 column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product.

20 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine:

 2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the
25 mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The
30 solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue
35 was purified on a 3.5 kg silica gel column, packed and

-36-

eluted with EtOAc/Hexane/Acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

5 3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine:

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and
10 acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by tlc by first quenching the tlc sample with the addition of MeOH. Upon completion of the reaction, as judged by tlc, MeOH (50 mL) was added and the mixture
15 evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and
20 evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%).

25 3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine:

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a
30 solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was
35 added dropwise, over a 45 minute period, to the later

-37-

solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine:

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100°C for 2 hours (tlc showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N⁴-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine:

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tlc showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO₄ and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica

-38-

column using EtOAc/Hexane (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N⁴-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite:

5 N⁴-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂ (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra(isopropyl)phosphite (40.5 mL, 0.123 M) were added
10 with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (tlc showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃ (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-
15 extracted with CH₂Cl₂ (300 mL), and the extracts were combined, dried over MgSO₄, and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc\Hexane (3:1) as the eluting solvent. The pure
20 fractions were combined to give 90.6 g (87%) of the title compound.

5-methyl-2'-deoxycytidine (5-me-C) containing oligonucleotides were synthesized according to published methods (Sanghvi et al., Nucl. Acids Res., 1993, 21, 3197-3203) using commercially available phosphoramidites (Glen
25 Research, Sterling VA or ChemGenes, Needham MA).

2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following
30 paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

-39-

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for

-40-

ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine

5'-O-tert-Butylidiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40),

-41-

to get 2'-O-([2-phthalimidooxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine as white foam (21.819, 86%).

5 5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidooxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 hr the mixture was
10 filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20%
15 aqueous solution, w/w, 1.1eq.) was added and the mixture for 1 hr. Solvent was removed under vacuum; residue chromatographed to get 5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95, 78%).

20 5'-O-tert-Butylidiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium
25 cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred
30 at room temperature for 2 hr, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in
35 MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was

-42-

added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

15 2'-O-(dimethylaminooxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-

25 (dimethylaminooxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine

2'-O-(dimethylaminooxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P₂O₅ under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum

-43-

and the residue chromatographed and eluted with 10% MeOH in CH_2Cl_2 (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P_2O_5 under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO_3 (40mL). Ethyl acetate layer was dried over anhydrous Na_2SO_4 and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

Oligonucleotides having methylene(methylimino) (MMI) backbones are synthesized according to U.S. Patent 5,378,825, which is coassigned to the assignee of the present invention and is incorporated herein in its entirety. For ease of synthesis, various nucleoside dimers containing MMI linkages were synthesized and incorporated into oligonucleotides. Other nitrogen-containing backbones are synthesized according to WO 92/20823 which is also coassigned to the assignee of the present invention and incorporated herein in its entirety.

-44-

Oligonucleotides having amide backbones are synthesized according to De Mesmaeker et al. (Acc. Chem. Res., 1995, 28, 366-374). The amide moiety is readily accessible by simple and well-known synthetic methods and is compatible with the conditions required for solid phase synthesis of oligonucleotides.

Oligonucleotides with morpholino backbones are synthesized according to U.S. Patent 5,034,506 (Summerton and Weller).

Peptide-nucleic acid (PNA) oligomers are synthesized according to P.E. Nielsen et al. (Science, 1991, 254, 1497-1500).

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al. (J. Biol. Chem., 1991, 266, 18162). Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 2: Oligonucleotide Sequences and Cell Culture

Antisense oligonucleotides were designed to E-selectin, Ha-ras, c-raf, JNK1, and JNK2. Additional sequences were designed as scrambled controls. The sequence of the oligonucleotides used are given in Table 1. All of these oligonucleotides except ISIS 11928 (SEQ ID NO. 1) contain 2'-O-methoxyethyl/phosphodiester residues flanking a 2'-deoxynucleotide/phosphorothioate region.

-45-

ISIS 11928 (SEQ ID NO. 1) is a fully phosphorothioated oligonucleotide with all 2'-methoxyethoxy nucleotides, except for a 3' terminal 2'-deoxy nucleotide. The target sequence for E-selectin was obtained from the Genbank
5 endothelial leukocyte adhesion molecule I exon 1 sequence, HUMELAM1 (Accession number M61895; SEQ ID NO. 8). The target sequence for Ha-ras was obtained from the Genbank Ha-ras sequence, HSRAS1 (Accession number V00574; SEQ ID NO. 10). The target sequence for *c-raf* was obtained from
10 the Genbank *c-raf* sequence, HSRAFR (Accession number X03484; SEQ ID NO. 12). The target sequence for JNK1 was obtained from the Genbank JNK1 sequence, HUMJNK1 (Accession number L26318; SEQ ID NO. 14). The target sequence for JNK2 was obtained from the Genbank JNK2 sequence, HUMJNK2
15 (Accession number L31951; SEQ ID NO. 16).

TABLE 1
Nucleotide Sequences of Mixed Backbone Chimeric (deoxy gapped) 2'-O-methoxyethyl
Oligonucleotides

NO.	ISIS	NUCLEOTIDE SEQUENCE (5' -> 3') ¹	SEQ		TARGET GENE
			ID	NO:	
5	11928	<u>G</u> s <u>A</u> s <u>A</u> s <u>G</u> s <u>T</u> s <u>C</u> s <u>A</u> s <u>G</u> s <u>C</u> s <u>C</u> s <u>A</u> s <u>A</u> s <u>G</u> s <u>A</u> s <u>C</u> s <u>A</u> s <u>G</u> s <u>C</u> s <u>T</u>	1		E-selectin
	12854	<u>T</u> o <u>C</u> o <u>C</u> o <u>C</u> o <u>G</u> o <u>C</u> s <u>C</u> s <u>T</u> s <u>G</u> s <u>T</u> s <u>G</u> s <u>A</u> s <u>C</u> s <u>A</u> s <u>T</u> o <u>G</u> o <u>C</u> o <u>A</u> o <u>T</u> o <u>T</u>	2		c-raf
	15727	<u>A</u> o <u>T</u> o <u>G</u> o <u>C</u> o <u>A</u> o <u>I</u> s <u>T</u> s <u>C</u> s <u>T</u> s <u>G</u> s <u>C</u> s <u>C</u> s <u>C</u> s <u>C</u> s <u>C</u> o <u>A</u> o <u>A</u> o <u>G</u> o <u>G</u> o <u>A</u>	3		12854 control
	15168	<u>T</u> o <u>C</u> o <u>C</u> s <u>G</u> s <u>T</u> s <u>C</u> s <u>A</u> s <u>T</u> s <u>C</u> s <u>G</u> s <u>C</u> s <u>T</u> s <u>C</u> o <u>C</u> o <u>T</u> o <u>C</u> o <u>A</u> o <u>G</u> o <u>G</u> o <u>G</u>	4		Ha-ras
	17552	<u>T</u> o <u>C</u> o <u>A</u> s <u>G</u> s <u>T</u> s <u>A</u> s <u>T</u> s <u>A</u> s <u>G</u> s <u>C</u> s <u>C</u> o <u>C</u> o <u>C</u> o <u>A</u> o <u>C</u> o <u>A</u> o <u>T</u> o <u>G</u> o <u>G</u>	5		15168 Control
10	15347	<u>C</u> o <u>T</u> o <u>C</u> o <u>T</u> o <u>C</u> o <u>I</u> s <u>G</u> s <u>T</u> s <u>A</u> s <u>G</u> s <u>G</u> s <u>C</u> s <u>C</u> s <u>C</u> s <u>G</u> s <u>C</u> o <u>T</u> o <u>T</u> o <u>G</u> o <u>G</u>	6		JNK1
	15354	<u>G</u> o <u>T</u> o <u>C</u> o <u>C</u> o <u>G</u> o <u>G</u> s <u>C</u> s <u>C</u> s <u>A</u> s <u>G</u> s <u>G</u> s <u>C</u> s <u>C</u> s <u>A</u> s <u>A</u> o <u>A</u> o <u>G</u> o <u>T</u> o <u>C</u>	7		JNK2

¹ Underlined residues are 2'-methoxyethoxy residues (others are 2'-deoxy-). All 2'-methoxyethoxy cytidines are 5-methyl-cytidines; "s" linkages are phosphorothioate linkages, "o" linkages are phosphodiester linkages.

-47-

Human dermal microvascular cells (HMVEC-d; Clonetics, San Diego, CA) were cultivated in endothelial basal media (EBM, Clonetics) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Cells were grown in 100 mm petri dishes until 70-80% confluent, then washed with PBS and OPTI-MEM (Life Technologies, Inc., Gaithersburg, MD). The cells were then incubated in the presence of OPTI-MEM and 3 mg/ml LIPOFECTIN (a 1:1 (w/w) liposome formulation of the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA), and dioleoyl phosphotidylethanolamine (DOPE) in membrane filtered water (Life Technologies, Gaithersburg, MD), per 100 nM of oligonucleotide followed by addition of oligonucleotide at the appropriate concentrations.

For determination of mRNA levels by Northern blot, total RNA was prepared from cells by the guanidinium isothiocyanate procedure or by the Qiagen RNAEASY method (Qiagen, Santa Clarita, CA) at the indicated times after initiation of oligonucleotide treatment. Northern blot analysis was performed as described in Current Protocols in Molecular Biology (Ausubel, F.M., et al., (eds), 1987, Greene Publishing Assoc. and Wiley Interscience, New York). A glyceraldehyde 3-phosphate dehydrogenase (G3PDH) probe was purchased from Clontech (Palo Alto, CA, Catalog Number 9805-1). RNA was quantified and normalized to G3PDH mRNA levels using a Molecular Dynamic PHOSPHORIMAGER (Sunnyvale, CA).

For determination of protein levels by Western blot, cellular extracts were prepared using 300 ml of RIPA extraction buffer per 100-mm dish. The protein concentration was quantified by Bradford assay using the BioRad kit (BioRad, Hercules, CA). Equal amounts of protein were loaded on 10% or 12% SDS-PAGE mini-gel (Novex, San Diego, CA). Once transferred to PVDF membranes (Millipore, Bedford, MA), the membranes were then treated

-48-

for a minimum of 2 hours with specific primary antibody followed by incubation with secondary antibody conjugated to HRP. The results were visualized by Enhanced Chemiluminescent (ECL) detection (New England BioLab, Beverly, MA). In some experiments, the blots were stripped in stripping buffer (2% SDS, 12.5 mM Tris, pH 6.8) for 30 minutes at 50°C. After extensive washing, the blots were blocked and blotted with different primary antibody.

Example 3: Inhibition of *c-raf* and *Ha-ras* Expression by Antisense Oligonucleotides

ISIS 12854 (SEQ ID NO. 2) is a 2'-O-methoxyethyl mixed backbone chimeric antisense oligonucleotide designed to hybridize with 3'-untranslated sequences contained within human *c-raf* mRNA. To determine whether this antisense oligonucleotide is effective as a *c-raf* inhibitor in endothelial cells, human dermal microvascular cells (HMVEC) were treated with ISIS 12854 (SEQ ID NO. 2) as described in Example 2. *C-raf* mRNA and protein expression was examined by northern and Western blot analysis. The *c-raf* cDNA probe was generated from the plasmid, p627 (American Type Culture Collection, Manassas, VA; catalog #41050), following the supplied instructions. The *c-raf* antibody was obtained from Transduction Laboratories, Inc. (Lexington, KY). Northern blot results are shown in Table 2. Western blot results are shown in Figure 1.

TABLE 2

Dose Response of ISIS 12854 on *c-raf* mRNA Levels in HMVEC Cells

ISIS #	SEQ ID NO:	ASO Gene Target	Dose	% mRNA	
				Expression	Inhibition
LIPOFECTIN	---	---	---	100%	---
15727	3	control	100 nM	96%	4%

-49-

	"	"	"	200 nM	135%	---
	12854	2	<i>c-raf</i>	0.5 nM	67%	33%
	"	"	"	2.5 nM	31%	69%
	"	"	"	10 nM	15%	85%
5	"	"	"	50 nM	10%	90%
	"	"	"	100 nM	13%	87%
	"	"	"	200 nM	3%	97%

Treatment of HMVEC with ISIS 12854 (SEQ ID NO. 2) resulted in dramatically reduced *c-raf* mRNA levels. Reduction of *c-raf* mRNA levels was dose-dependent in the range of 0.5 to 200 nM. The IC₅₀ for *c-raf* mRNA reduction was approximately 2.5 nM. The control oligonucleotide, ISIS 15727 (SEQ ID NO. 3) did not exhibit any effect on *c-raf* mRNA.

Reduction of *c-raf* protein levels also occurred following oligonucleotide treatment. Reduction in protein expression was first detectable 24 hours after treatment and maximal reduction of *c-raf* protein levels was achieved 48 hours after treatment with 150 nM oligonucleotide. Reduction of *c-raf* protein levels persisted up to 72 hour following initial treatment. Inhibition of *c-raf* expression by ISIS 12854 (SEQ ID NO. 2) was specific since A-*raf* protein expression was largely unaffected when the same blot was stripped and blotted with antibody against A-*raf* (Transduction Laboratories, Inc., Lexington, KY).

ISIS 15168 (SEQ ID NO. 4) is a 2'-O-methoxyethyl mixed backbone chimeric antisense oligonucleotide designed to hybridize with sequences contained within the human Ha-*ras* mRNA. To determine the effect of ISIS 15168 (SEQ ID NO. 4) on Ha-*ras* expression in endothelial cells, HMVEC were treated, as described in Example 2, with oligonucleotide and northern blotting was used to measure Ha-*ras* mRNA levels. A Ha-*ras* probe was generated from the plasmid,

-50-

pbcc-N1 (American Type Culture Collection, Manassas, VA; catalog #41001), following the supplied instructions. Results are shown in Table 3.

TABLE 3

5 **Dose Response of Ha-ras Antisense Oligodeoxynucleotides on Ha-ras mRNA Levels in HMVEC Cells**

	ISIS #	SEQ ID NO:	ASO Gene Target	Dose	% mRNA Expression	% mRNA Inhibition
	LIPOFECTIN™	---	---	---	100%	---
10	15168	4	Ha-ras	1 nM	61%	39%
	"	"	"	5 nM	44%	56%
	"	"	"	25 nM	19%	81%
	"	"	"	50 nM	10%	90%
	"	"	"	100 nM	9%	91%
15	17552	5	control	1 nM	103%	---
	"	"	"	5 nM	115%	---
	"	"	"	25 nM	96%	4%
	"	"	"	50 nM	109%	---
	"	"	"	100 nM	105%	---

20

Reduction of Ha-ras mRNA levels in HMVEC was observed following oligonucleotide treatment and was found to be sequence-specific, and dose-dependent ($IC_{50} < 5$ nM).

To examine the effect of ISIS 15168 (SEQ ID NO. 4) on Ha-ras protein levels, total ras protein was immunoprecipitated using a pan-ras monoclonal antibody (Oncogene Science, Cambridge, MA). The precipitated proteins were analyzed by SDS-PAGE, and Ha-ras protein levels were determined by western blot using a monoclonal antibody specific for Ha-ras (Oncogene Science, Cambridge, MA). As shown in Figure 2, dose-dependent reduction of Ha-ras protein expression was observed 48 hours following treatment with ISIS 15168 (SEQ ID NO. 4). This reduction

30

-51-

persisted up to 72 hours following initial treatment. The kinetics of Ha-ras reduction was slower than that of *c-raf*. The control oligonucleotide, ISIS 17552 (SEQ ID NO. 5), had no effect on Ha-ras protein level. The same blot was
5 stripped and blotted a second time with a Ki-ras-specific antibody (Oncogene Science, Cambridge, MA). No effect on Ki-ras protein levels was observed in cells treated with either ISIS 15168 (SEQ ID NO. 4) or the control oligonucleotide, ISIS 17552 (SEQ ID NO. 5).

10 **Example 4: Effect of inhibiting *c-raf* and Ha-ras Gene Expression on the Induction of E-selectin**

The effect of *c-raf* and Ha-ras antisense oligonucleotide treatment on the induction of E-selectin by TNF- α was examined. HMVEC cells were treated with either
15 the *c-raf* or Ha-ras antisense compound under dose-response conditions or over time at a single dose level followed by stimulation of E-selectin expression by TNF- α for 5 hours. The cell surface expression of E-selectin was determined by flow cytometry analysis. Following oligonucleotide
20 treatment, cells were detached from the plates and analyzed for surface expression of cell adhesion molecules using a Becton Dickinson (San Jose, CA) FACScan. TNF- α and FITC conjugated antibody for E-selectin were obtained from R & D Systems (Minneapolis, MN). PE-conjugated antibody for
25 ICAM-1 was obtained from Pharmingen (San Diego, CA). VCAM-1 antibody was obtained from Santa Cruz Biotechnology, Santa Cruz, CA. Cell surface expression was calculated using the mean value of fluorescence intensity using 3,000-5,000 cells stained with the appropriate antibody for each
30 sample and time point. Results are expressed as percentage of control (cell surface expression induced by TNF- α in cells that were not treated with oligonucleotides) based upon mean fluorescence intensity. Results are shown in Tables 4 and 5. Basal expression of E-selectin and VCAM-1

-52-

is undetectable in the absence of TNF- α whereas a low level of basal expression is detectable for ICAM-1.

ABLE 4

Dose Response of the effect of *c-raf* and Ha-*ras* Antisense Oligonucleotides in Induction of E-selectin

	ISIS #	SEQ ID NO:	ASO Gene Target	Dose	% Cell Surface Expression	% Cell Surface Inhibition
	LIPOFECTIN™	---	---	---	100%	---
	12854	2	<i>c-raf</i>	25 nM	37%	63%
10	"	"	"	75 nM	26%	74%
	"	"	"	150 nM	23%	77%
	15727	3	control	25 nM	119%	---
	"	"	"	75 nM	94%	6%
	"	"	"	150 nM	106%	---
15	15168	4	Ha- <i>ras</i>	25 nM	72%	28%
	"	"	"	75 nM	47%	53%
	"	"	"	150 nM	41%	59%
	17552	5	control	25 nM	134%	---
	"	"	"	75 nM	116%	---
20	"	"	"	150 nM	116%	---

Dose-dependent inhibition of E-selectin cell surface expression was observed in cells treated with both antisense compounds, ISIS 12854 (SEQ ID NO. 2), targeted to *c-raf* and ISIS 15168 (SEQ ID NO. 4) targeted to Ha-*ras*. Maximal inhibition of E-selectin induction was approximately 80% for ISIS 12854 (SEQ ID NO. 2) and 60% for ISIS 15168 (SEQ ID NO. 4). Control oligonucleotides (SEQ ID NO. 3 and SEQ ID NO. 5) exhibited little to no effect on E-selectin induction. These results indicate that reduction of *c-raf* or Ha-*ras* protein levels blocked the induction of E-selectin by TNF- α in HMVEC.

The effects of *c-raf*, Ha-*ras*, and a E-selectin antisense oligonucleotide on TNF- α -induced E-selectin cell

-53-

surface expression under kinetic conditions were examined. If the inhibition of E-selectin induction by the *c-raf* and Ha-ras antisense compounds was dependent on the reduction of *c-raf* and Ha-ras protein levels, the kinetics of inhibition of E-selectin induction by the antisense compounds should correlate with suppression of *c-raf* and Ha-ras protein levels (which is dependent on the half-lives of the proteins in cells). Inhibition of E-selectin induction using the E-selectin antisense oligonucleotide should occur much more quickly since this inhibitor blocks E-selectin induction directly. To test this, cells were treated, separately, with antisense oligonucleotides to E-selectin, ICAM-1 and VCAM-1 and allowed to recover prior to TNF- α treatment. TNF- α was added at different time points between 12 and 72 hours following oligonucleotide treatment. E-selectin cell surface expression was measured by flow cytometry analysis after 5 hours of TNF- α treatment. Results are shown in Table 5.

TABLE 5

Time Course of the Effect of *c-raf* and Ha-ras Antisense Oligonucleotides in Induction of E-selectin

ISIS #	SEQ ID NO:	ASO Gene Target	Time (hours)	% Cell Surface Expression	% Cell Surface Inhibition
LIPOFECTIN	---	---	---	100%	---
25 11928	1	E-selectin	12h/20h	22%	78%
"	"	"	48h	29%	71%
"	"	"	72h	32%	68%
12854	2	<i>c-raf</i>	12h/20h	58%	42%
"	"	"	48h	23%	77%
30 "	"	"	72h	24%	76%
15727	3	control	12h/20h	93%	7%

-54-

	"	"	"	48h	106%	---
	"	"	"	72h	81%	19%
	15168	4	Ha-ras	12h/20h	87%	13%
	"	"	"	48h	42%	58%
5	"	"	"	72h	42%	58%
	17552	5	control	12h/20h	113%	---
	"	"	"	48h	116%	---
	"	"	"	72h	111%	---

10 Concentrations as low as 20 nM of the E-selectin oligonucleotide, ISIS 11928 (SEQ ID NO. 1) were found to block 80% of E-selectin cell surface expression 12 hours following treatment. In contrast, maximal inhibition of E-selectin induction by *c-raf* and Ha-ras antisense compounds, 15 SEQ ID NO. 2 and SEQ ID NO. 4, respectively, was observed 48 hours following antisense treatment. Some inhibition of E-selectin induction was observed at 12 hours following treatment, but this inhibition was clearly not maximal. These results strongly suggest that inhibition of E-selectin induction by TNF- α in HMVEC following treatment with *c-raf* and Ha-ras antisense oligonucleotides is a consequence of reduced *c-raf* and Ha-ras protein levels.

Example 5: Effect of *c-raf* and Ha-ras Antisense

Oligonucleotides on the Induction of other Cell Adhesion

25 Molecules

TNF- α induction of ICAM-1 and VCAM-1 in cells treated with *c-raf* and Ha-ras antisense oligonucleotides was also examined to further define the roles of *c-raf* and Ha-ras in cytokine signaling. Oligonucleotides were tested, using 30 flow cytometry analysis, as described in Example 4. Results are shown in Table 6 (ICAM-1) and Table 7 (VCAM-1).

-55-

TABLE 6

Dose response of the effect of *c-raf* and *Ha-ras* antisense oligonucleotides in induction of ICAM-1

		SEQ	ASO		% Cell	% Cell
5	ISIS #	ID	Gene	Dose	Surface	Surface
		NO:	Target	(conc.)	Expression	Inhibition
	LIPOFECTIN™	---	---	---	100%	---
	12854	2	<i>c-raf</i>	20 nM	80%	20%
	"	"	"	50 nM	62%	38%
	"	"	"	100 nM	57%	43%
10	15727	3	control	20 nM	97%	3%
	"	"	"	50 nM	89%	11%
	"	"	"	100 nM	87%	13%
	15168	4	<i>Ha-ras</i>	20 nM	81%	19%
	"	"	"	50 nM	62%	38%
15	"	"	"	100 nM	54%	46%
	17552	5	control	20 nM	102%	---
	"	"	"	50 nM	100%	---
	"	"	"	100 nM	98%	2%

20 Induction of ICAM-1 by TNF- α was also blocked by *c-raf* (ISIS 12854, SEQ ID NO. 2) and *Ha-ras* (ISIS 15168, SEQ ID NO. 4) antisense oligonucleotides, with maximal inhibition greater than 40%.

25 Treatment of cells with *c-raf* and *Ha-ras* antisense oligonucleotides inhibited VCAM-1 expression in a dose-dependent fashion as well. Results are shown in Table 7.

-56-

TABLE 7

Dose response of the effect of *c-raf* and Ha-*ras* antisense oligonucleotides in induction of VCAM-1

5	ISIS #	SEQ	ASO	Dose	% Cell	% Cell
		ID	Gene		Surface	Surface
		NO:	Target	(conc.)	Expression	Inhibition
	LIPOFECTIN™	---	---	---	100%	---
	12854	2	<i>c-raf</i>	20 nM	46%	54%
	"	"	"	50 nM	37%	63%
	"	"	"	100 nM	28%	72%
10	15727	3	control	20 nM	69%	31%
	"	"	"	50 nM	81%	19%
	"	"	"	100 nM	74%	26%
	15168	4	Ha- <i>ras</i>	20 nM	70%	30%
	"	"	"	50 nM	51%	49%
15	"	"	"	100 nM	44%	56%
	17552	5	control	20 nM	111%	---
	"	"	"	50 nM	97%	3%
	"	"	"	100 nM	85%	15%

20 Induction of VCAM-1 by TNF- α was also blocked by *c-raf* (ISIS 12854, SEQ ID NO. 2) and Ha-*ras* (ISIS 15168, SEQ ID NO. 4) antisense oligonucleotides. Maximum inhibition for ISIS 12854 (SEQ ID NO. 2) was greater than 70%, while maximum inhibition for ISIS 15168 (SEQ ID NO. 4) was greater than 50%.

Example 6: Effect of *c-raf* and Ha-*ras* Antisense Oligonucleotides on Cell Adhesion Molecule mRNA levels

Northern blot analysis was carried out to examine whether *c-raf* and Ha-*ras* antisense oligonucleotides inhibit the induction of cell adhesion molecules at the transcriptional level. Cells were treated with *c-raf* (ISIS

-57-

12854, SEQ ID NO. 2) or Ha-ras (ISIS 15168, SEQ ID NO. 4) antisense oligonucleotides and allowed to recover for 48 hrs. TNF- α was added two to three hours prior to RNA analysis and Northern blotting was performed with probes specific for E-selectin, ICAM-1, and VCAM-1. The probe for E-selectin was obtained by PCR amplification using primers directed to HUMELAM1A (Genbank Accession No. M24736; SEQ ID NO. 18).

The probe for ELAM-1 was obtained by PCR amplification using the following primers:

FORWARD 5'-TTGAAGTCATGATTGCTTCACAGTT-3' SEQ ID NO. 20

REVERSE 5'-TTCTGATTCTTTTGAAGCTTAAAGGAT-3' SEQ ID NO. 21

The probe for ICAM-1 was obtained by PCR amplification using the following primers:

FORWARD 5'-CGCGGATCCGCGTACTCAGAGTT-3' SEQ ID NO. 22

REVERSE 5'-CGGAATTCCGTTTCAGGGAGGCGT-3' SEQ ID NO. 23

The probe for VCAM-1 was obtained by PCR amplification using the following primers:

FORWARD 5'-CTTAAATGCCTGGGAAGATGGTCGT-3' SEQ ID NO. 24

REVERSE 5'-ATCAAGCATTAGCTACACTTTTGATT-3' SEQ ID NO. 25

Results are shown in Table 8.

TABLE 8

Effect of *c-raf* and Ha-ras antisense oligonucleotides on induction of E-selectin, VCAM-1, and ICAM-1

ISIS #	SEQ ID NO:	ASO Gene Target	Cell adhesion molecule	% mRNA Expression	% mRNA Inhibition
LIPOFECTIN™	---	---	---	100%	---
12854	2	<i>c-raf</i>	E-selectin	22%	78%
"	"	"	ICAM-1	78%	22%
"	"	"	VCAM-1	35%	65%
15727	3	contro	E-selectin	103%	---

-58-

	"	"	"	ICAM-1	107%	---
	"	"	"	VCAM-1	113%	---
	15168	4	Ha-ras	E-selectin	13%	87%
	"	"	"	ICAM-1	73%	27%
5	"	"	"	VCAM-1	29%	71%
	17552	5	contro	E-selectin	92%	8%
		1				
	"	"	"	ICAM-1	101%	---
	"	"	"	VCAM-1	111%	---

10 Induction of mRNA expression of the three cell
adhesion molecules was attenuated by both antisense
oligonucleotides, whereas treatment with control
oligonucleotides exhibited little to no effect. The level
of inhibition for each cell adhesion molecule at the mRNA
15 level was consistent with the effects of *c-raf* and Ha-ras
antisense treatment on the cell surface expression of cell
adhesion molecules.

**Example 7: Effect of *c-raf* Antisense Oligonucleotides on
MAP Kinase Activities**

20 To examine the effect of the *c-raf* antisense
oligonucleotide (ISIS 12854, SEQ ID NO. 2) on ERK, JNK, and
p38 MAPK activities stimulated by TNF- α , *in vitro* kinase
assays were performed on extracts derived from cells
treated with ISIS 12854 (SEQ ID NO. 2). Cells were treated
25 with oligonucleotides and induced with cytokines. At the
indicated time, cells were lysed on ice and debris was
removed by centrifugation. Protein concentration was
measured by Bradford assay. Lysate containing equal
amounts of protein were incubated with primary antibody-
30 agarose conjugates (ERK and p38 assay; Santa Cruz
Biotechnology, Santa Cruz, CA), or with JNK1-specific or
JNK2-specific antibodies (JNK assay; Upstate Biotechnology,
Lake Placid, NY), overnight at 4°C.

-59-

For isoform-specific JNK assays, anti-rabbit IgG conjugated with agarose beads was added to cell extracts following JNK antibody treatment and wash steps and incubated for 2 hours at 4°C. After washing with lysis
5 buffer and kinase buffer, the pelleted beads were incubated with 1 µg of substrate (Elk-1 for ERK, ATF-2 for p38, and c-Jun for JNK MAPK) and 100 αM of ATP for 20 minutes at 37°C. MAPK and JNK assay kits, ATF-2 fusion protein, and
10 antibodies for ATF-2, Elk-1 phospho-ATF-2 were purchased from New England BioLabs (Boston, MA). Reactions were terminated by the addition of 3x SDS sample buffer followed by boiling. The samples were loaded on 12% SDS-PAGE gels. Western blot with antibodies specific for phosphorylated substrates (New England Biolabs) was carried out. The
15 results were visualized by ECL.

Cells were treated with the *c-raf* antisense compound, ISIS 12854 (SEQ ID NO. 2), allowed to recover for 48 hours, at which time TNF-α was added for 5 or 15 minutes prior to cell lysis and initiation of the kinase assays. Specific
20 antibody-conjugated agarose beads were used to immunoprecipitate ERK and p38 MAPK, and c-Jun-conjugated agarose beads were used to precipitate JNK. Suitable substrates and ATP were added to the immunoprecipitated kinase complexes and the reaction mixes were analyzed on
25 SDS-PAGE. Western blotting with antibodies specific for phosphorylated substrates was carried out to determine relative kinase activity. Results are shown in Figure 3.

All three kinases were activated by TNF-α after a 15 minutes incubation, as indicated by the heavy
30 phosphorylation of the three substrates. Inhibition of *c-raf* levels by ISIS 12854 (SEQ ID NO. 2) resulted in reduced ERK activity. Surprisingly, JNK activity was also inhibited by treating cells with ISIS 12854 (SEQ ID NO. 2). Activation of p38 MAPK was not affected by *c-raf* antisense
35 treatment.

-60-

These results demonstrate for the first time that *c-raf* inhibition blocks TNF- α -mediated induction of cell adhesion molecules by suppressing the JNK pathway.

Antisense oligonucleotides targeted against JNK1 (SEQ ID NO. 6) or JNK2 (SEQ ID NO. 7) were tested for their abilities to inhibit JNK expression, JNK activity and E-selectin induction by TNF- α .

Oligonucleotide treatment, RNA isolation and Northern blots were performed as described in Example 2. A cDNA clone of JNK1 (Derijard et al., *Cell*, 1994, 76, 1025) was radiolabeled and used as a JNK1-specific probe. A cDNA clone of JNK2 (Kallunki et al., *Genes & Development*, 1994, 8, 2996) was radiolabeled and used as a JNK2-specific probe. JNK1 and JNK2 antisense treatment resulted in nearly complete inhibition of JNK1 and JNK2 mRNA expression, respectively, as shown in Figure 4.

Furthermore, both antisense oligonucleotides were isoform-specific at the employed concentrations. The JNK2 antisense molecule will inhibit JNK1 expression slightly at higher oligonucleotide concentrations due to the fact that it is complementary to JNK1 mRNA in 17 of its 20 bases. However, at the concentration tested, the JNK2 antisense oligonucleotide specifically inhibits JNK2 expression without affecting JNK1 levels. Treatment of cells with either JNK1 or JNK2 antisense effectively reduced TNF- α -mediated induction of JNK activity in an isoform-specific manner, as shown in Figure 5. However, JNK2 antisense treatment resulted in substantially greater inhibition of TNF- α -mediated induction of E-selectin cell surface expression relative to JNK1 antisense treatment. Results are shown in Table 9. These results further confirm that the involvement of *c-raf* in TNF- α -mediated induction of cell adhesion molecules in HMVEC involves the regulation of JNK and that this regulation is believed to be specific for the JNK2 isoform.

-61-

TABLE 9

Dose Response of the Effect of JNK Antisense
Oligonucleotides in induction of E-selectin

5	ISIS #	SEQ	ASO	Time	% Cell	% Cell
		ID	Gene		Surface	Surface
		NO:	Target	(hours)	Expression	Inhibition
	LIPOFECTIN	---	---	---	100%	---
	15347	6	JNK1	20 nM	89%	11%
	"	"	"	50 nM	84%	16%
	"	"	"	100 nM	82%	18%
10	15354	7	JNK2	20 nM	32%	68%
	"	"	"	50 nM	29%	71%
	"	"	"	100 nM	33%	67%
	15727	3	control	20 nM	137%	---
	"	"	"	50 nM	128%	---
15	"	"	"	100 nM	124%	---

-62-

WHAT IS CLAIMED IS:

1. A method of modulating cell adhesion molecule expression comprising treating a cell expressing a cell adhesion molecule with a specific inhibitor of a Tumor
5 Necrosis Factor alpha signaling molecule selected from the group consisting of Ha-ras, c-raf and JNK2, such that cell adhesion molecule expression is modulated.
2. The method of claim 1 wherein said cell adhesion
10 molecule is E-selectin, VCAM-1 or ICAM-1.
3. The method of claim 1 wherein said inhibitor is an antisense oligonucleotide specifically hybridizable with a nucleic acid encoding Tumor Necrosis Factor alpha signaling
15 molecule.
4. The method of claim 3 wherein said Tumor Necrosis Factor alpha signaling molecule is Ha-ras or c-raf.
- 20 5. The method of claim 4 wherein said antisense oligonucleotide is hybridizable to Ha-ras or c-raf.
6. The method of claim 5 wherein said antisense oligonucleotide has a sequence comprising SEQ ID NO. 2 or
25 SEQ ID NO. 4.
7. The method of claim 6 wherein said antisense oligonucleotide has at least one phosphorothioate internucleotide linkage.
30
8. The method of claim 6 wherein said antisense oligonucleotide has at least one 2'-methoxyethoxy nucleotide.

-63-

9. The method of claim 1 wherein said cell adhesion molecule is E-selectin and said Tumor Necrosis Factor alpha signaling molecule is JNK-2.

5 10. The method of claim 9 wherein said inhibitor is an antisense oligonucleotide specifically hybridizable with a nucleic acid encoding JNK-2.

11. The method of claim 10 wherein said antisense
10 oligonucleotide has a sequence comprising SEQ ID NO. 7.

12. The method of claim 11 wherein said antisense
oligonucleotide has at least one phosphorothioate
internucleotide linkage.

15 13. The method of claim 11 wherein said antisense
oligonucleotide has at least one 2'-methoxyethoxy
nucleotide.

20 14. A method of inhibiting expression of a MAP kinase
within a cell comprising treating said cell with a specific
inhibitor of *c-raf*.

15. The method of claim 14 wherein said inhibitor is an
25 antisense oligonucleotide specifically hybridizable with a
nucleic acid encoding *c-raf*.

16. The method of claim 15 wherein said oligonucleotide
comprises SEQ ID NO. 2.

30 17. The method of claim 16 wherein said antisense
oligonucleotide has at least one phosphorothioate
internucleotide linkage.

-64-

18. The method of claim 16 wherein said antisense oligonucleotide has at least one 2'-methoxyethoxy nucleotide.

5 19. A method of treating a disease or condition associated with altered expression of a cell adhesion molecule comprising administering a specific inhibitor of a Tumor Necrosis Factor alpha signaling molecule selected from the group consisting of Ha-ras, c-raf and JNK2, under
10 conditions wherein expression of said cell adhesion molecule is modulated.

20. The method of claim 19 wherein said disease or condition is an inflammatory or immune disease or
15 condition.

21. The method of claim 19 wherein said disease is sepsis, rheumatoid arthritis, inflammatory bowel disease, allergic contact dermatitis, psoriasis, diabetes, Grave's disease,
20 allograft rejection or cancer.

22. The method of claim 19 wherein said inhibitor is an antisense oligonucleotide specifically hybridizable with a nucleic acid encoding Tumor Necrosis Factor alpha signaling
25 molecule.

23. The method of claim 22 wherein said antisense oligonucleotide has a sequence comprising SEQ ID NO. 2, SEQ ID NO. 4 or SEQ ID NO. 7.
30

24. The method of claim 23 wherein said antisense oligonucleotide has at least one phosphorothioate internucleotide linkage.

-65-

25. The method of claim 23 wherein said antisense oligonucleotide has at least one 2'-methoxyethoxy nucleotide.

5 26. An inhibitor of a Tumor Necrosis Factor alpha signaling molecule selected from the group consisting of Ha-ras, c-raf and JNK2, wherein said inhibitor modulates expression of a cell adhesion molecule.

10 27. The inhibitor of claim 26 wherein said cell adhesion molecule is E-selectin, VCAM-1 or ICAM-1.

15 28. The inhibitor of claim 26 comprising an antisense oligonucleotide specifically hybridizable with a nucleic acid encoding a Tumor Necrosis Factor alpha signaling molecule.

29. The inhibitor of claim 27 wherein said tumor Necrosis Facotr alpha signaling molecule is Ha-ras or c-raf.

20 30. The inhibitor of claim 28 wherein said antisense oligonucleotide is hybridizable to Ha-ras or c-raf.

25 31. The inhibitor of claim 30 wherein said antisense oligonucleotide has a sequence comprising SEQ ID NO. 2 or SEQ ID NO. 4.

30 32. The inhibitor of claim 31 wherein said antisense oligonucleotide has at least one phosphorothioate internucleotide linkage.

33. The inhibitor of claim 31 wherein said antisense oligonucleotide has at least one 2'-methoxyethoxy nucleotide.

-66-

34. The inhibitor of claim 26 wherein said cell adhesion molecule is E-selectin and said Tumor Necrosis Factor alpha signaling molecule is JNK-2.

5 35. The inhibitor of claim 34 comprising an antisense oligonucleotide specifically hybridizable with a nucleic acid encoding JNK-2.

10 36. The inhibitor of claim 35 wherein said antisense oligonucleotide has a sequence comprising SEQ ID NO. 7.

15 37. The inhibitor of claim 36 wherein said antisense oligonucleotide has at least one phosphorothioate internucleotide linkage.

38. The method of claim 36 wherein said antisense oligonucleotide has at least one 2'-methoxyethoxy nucleotide.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

SEQUENCE LISTING

<110> Monia, Brett P.
Xu, Xiaoxing S.
Isis Pharmaceuticals, Inc.

<120> METHODS OF MODULATING TUMOR NECROSIS FACTOR
alpha-INDUCED EXPRESSION OF CELL ADHESION MOLECULES

<130> ISPH-0424

<150> US 09/209,668

<151> 1998-12-10

<160> 25

<170> PatentIn Ver. 2.0

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> antisense sequence

<400> 1
gaagtcagcc aagaacagct 20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> antisense sequence

<400> 2
tcccgctgt gacatgcatt 20

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> control sequence

<400> 3
atgcattctg cccccaagga 20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> antisense sequence

<400> 4
 tccgtcatcg ctccctcaggg 20

<210> 5
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> control sequence

<400> 5
 tcagtaatag cccacatgg 20

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antisense sequence

<400> 6
 ctctctgtag gcccgcttgg 20

<210> 7
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antisense sequence

<400> 7
 gtccgggcca ggccaaagtc 20

<210> 8
 <211> 1072
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (882)..(917)

<300>
 <308> M61895/Genbank
 <309> 1994-11-07

<400> 8
 atccacagct atgaatgaga aattgaaggt agtagactat ggatgacaaa cctattcttg 60
 gtttccttct gtttctgaaa ttctaattac taccacaact acatgagaga cactactaac 120
 aagcaaagtt ttacaacttt ttaaagacat agactttatg ttattataat taaaaatcat 180
 gcatttttgt catattaata aaattgcata tacgatataa aggcattggac aaaggtgaag 240
 tagcttcaag agacagagtt tctgacatca ttgtaatttt aagcatcgtg gatattcccg 300

```

ggaaagtttt tggatgccat tggggatttc ctctttactg gatgtggaca atatcctcct 360
attattcaca ggaagcaatc cctcctataa aagggcctca gccgaagtag tgttcagctg 420
ttcttggctg acttcacatc aaaactccta tactgacctg agacagaggc agcagtgata 480
cccacctgag agatcctgtg tttgaacaac tgcttcccaa aacggtaagt gcagaacgct 540
ttataagggc agcctcgggc catgaaacac agatatgcaa aaggccttct aataaaaacc 600
acatctgtac aagctcttat tgtattgtag ctaaaacctg tcttttctct ttgacctaaa 660
taatgaaagt cttaaaattt gtttatttat ttgattaaac tctgaaataa agattattgc 720
actagtgtcc ttgccccaaa atcttaggat gctgccttaa acatcatggt agaataatgt 780
aactagctac ccacgatttc cttctttaat tcatttgtgt tttatctccc caggaaagta 840
tttcaagcct aaacctttgg gtgaaaagaa ctcttgaagt c atg att gct tca cag 896
                                     Met Ile Ala Ser Gln
                                     1           5

ttt ctc tca gct ctc act ttg ggtaagtcag tgccattaga ccaagatttc      947
Phe Leu Ser Ala Leu Thr Leu
                        10

tcattctcgc actatagata tttcagactg aaatatectt gcttgtctgg ggctgtcctg 1007
cacaggatat ctggcagcat ccttgacctc tacctgcaat gtgttcttcc ctgggcttgg 1067
ggtca                                                    1072

```

<210> 9
 <211> 12
 <212> PRT
 <213> Homo sapiens

<400> 9
 Met Ile Ala Ser Gln Phe Leu Ser Ala Leu Thr Leu
 1 5 10

<210> 10
 <211> 6453
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1664)..(1774)

<220>
 <221> CDS
 <222> (2042)..(2220)

<220>
 <221> CDS
 <222> (2374)..(2533)

<220>
 <221> CDS
 <222> (3231)..(3350)

<300>

<308> V00574/Genbank

<309> 1991-01-03

<400> 10

ggatcccagc ctttcccag cccgtagccc cgggacctcc gcggtgggag gcgcccgcgt 60
gccggcgagc ggagggcctc tgggtgcaccg gcaccgctga gtcgggttct ctgcgggcc 120
tgttcccggg agagcccggg gccctgctcg gagatgccgc cccgggcccc cagacaccgg 180
ctccctggcc ttccctgagc aaccccagc tcggctccgg tctccagcca agcccaaccc 240
cgagaggccg cgccctact ggctccgcct cccgcgttgc tcccgaagc cccgcccagc 300
cgcggtcct gacagacggg ccgctcagcc aaccggggtg gggcggggcc cgatggcgcg 360
cagccaatgg taggccgcgc ctggcagacg gacgggcgcg gggcggggcg tgcgcaggcc 420
cgcccagagc tccgcggccc gtgccctgcg cccgcaaccc gagccgcacc cgccgcggac 480
ggagcccatg cgcgggggcga accgcgcgc cccgcccccg ccccgccccg gcctcggccc 540
cgccctggc cccgggggca gtcgcgcctg tgaacggtga gtgcgggcag ggatcggccg 600
ggcgcgcgc cctcctcgcc ccagggcgcc agcaatacgc gcggcgcggg ccggggggcg 660
ggggccggcg ggcgtaagcg gcggcggcg cggcgggtg gtggggccgg gcggggcccc 720
cgggcacagg tgagcgggag tcgggggctg cggcgggcg gggccccttc ctccctggg 780
cctgcgggaa tccgggcccc acccgtggcc tcgcgtggg cacggtcccc acgcccggcg 840
accggggagc ctgcggcccc gcgcctcac acccgggggc gtctgggagg aggcggccgc 900
ggccacggca cgcccgggca ccccgattc agcatcacag gtcgcggacc aggcggggg 960
cctcagcccc agtgcccttt ccctctccg gtctcccgc ccgcttctcg gcccttct 1020
gtcgtcagt ccctgcttc caggagctcc tctgtcttct ccagcttct gtggctgaaa 1080
gatgccccg gttccccgc gggggtgagg ggcgtgccc gggctctgcc tcccctcgcc 1140
ggcgctagt acgcagtagg cgtcagcaa atacttgctg gaggcaccag cgccgcgggg 1200
cctgcaggct ggcactagcc tgcccgggca cgccgtggcg cgtccgccc tggccagacc 1260
tgttctggag gacggtaac tcagccctcg ggcgcctccc tttagccttt ctgccgacc 1320
agcagcttct aatttggtg cgtggttgag agcgtcagc tgtcagccct gcctttgagg 1380
gctgggtccc ttttcccatc actgggtcat taagagcaag tgggggagc gcgacagccc 1440
tcccgcagc tgggttgag ctgcacaggt aggcacgctg cagtccctgc tgccctggcg 1500
tggggcccag ggaccgctgt gggtttgccc ttcagatggc cctgccagca gctgccctgt 1560
ggggcctggg gctgggcctg ggccctggct agcagggccc tccctggcag gtggggcagg 1620
agaccctgta ggaggacccc gggccgcagg cccctgagga gcg atg acg gaa tat 1675
Met Thr Glu Tyr

1

aag ctg gtg gtg gtg ggc gcc ggc ggt gtg ggc aag agt gcg ctg acc 1723
Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys Ser Ala Leu Thr
5 10 15 20

atc cag ctg atc cag aac cat ttt gtg gac gaa tac gac ccc act ata 1771
Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr Asp Pro Thr Ile
25 30 35

gag gtgagcctgg cgccaccgtc caggtgccag cagctgctgc gggcgagccc 1824
Glu

aggacacagc caggataggg ctggctgcag cccctggctcc cctgcatggt gctgtggccc 1884
tgtctcctgc ttcctctaga ggaggggagt ccctcgtctc agcaccaccag gagaggaggg 1944
ggcatgaggg gcatgagagg taccagggag aggctggctg tgtgaactcc cccacggaa 2004
ggtcctgagg gggccctga gccctgtcct cctgcag gat tcc tac cgg aag cag 2059
Asp Ser Tyr Arg Lys Gln
40

gtg gtc att gat ggg gag acg tgc ctg ttg gac atc ctg gat acc gcc 2107
Val Val Ile Asp Gly Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala
45 50 55

ggc cag gag gag tac agc gcc atg cgg gac cag tac atg cgc acc ggg 2155
Gly Gln Glu Glu Tyr Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly
60 65 70 75

gag ggc ttc ctg tgt gtg ttt gcc atc aac aac acc aag tct ttt gag 2203
Glu Gly Phe Leu Cys Val Phe Ala Ile Asn Asn Thr Lys Ser Phe Glu
80 85 90

gac atc cac cag tac agg tgaacccgt gaggtggcc cgggagccca 2251
Asp Ile His Gln Tyr Arg
95

cgccgcacag gtggggccag gccggctgcg tccaggcagg ggctcctgt cctctctgcg 2311
catgtcctgg atgccgtgc gcctgcagcc ccctagcca gctctcgctt tccacctctc 2371

agg gag cag atc aaa cgg gtg aag gac tcg gat gac gtg ccc atg gtg 2419
Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
100 105 110

ctg gtg ggg aac aag tgt gac ctg gct gca cgc act gtg gaa tct cgg 2467
Leu Val Gly Asn Lys Cys Asp Leu Ala Ala Arg Thr Val Glu Ser Arg
115 120 125

cag gct cag gac ctc gcc cga agc tac ggc atc ccc tac atc gag acc 2515
Gln Ala Gln Asp Leu Ala Arg Ser Tyr Gly Ile Pro Tyr Ile Glu Thr
130 135 140

tcg gcc aag acc cgg cag gtgaggcagc tctccacccc acagctagcc 2563
Ser Ala Lys Thr Arg Gln
145 150

agggaccgc cccgccccgc ccagccagg gagcagcaact cactgaccct ctcccttgac 2623
acagggcagc cgctctggct ctagctccag ctccgggacc ctctgggacc cccgggacc 2683
catgtgaccc agcggccct cgcgctgtaa gtctcccggg acggcagggc agtgagggag 2743

gcgagggccg ggggtctgggc tcacgccctg cagtcctggg ccgacacagc tccggggaag 2803
 gcggaggtcc ttggggagag ctgccctgag ccaggccgga gcggtgaccc tggggcccgg 2863
 cccctcttgt cccagagtg tcccacgggc acctgttggg tctgagtcct agtggggcta 2923
 ctggggacac gggccgtagc tgagtcgaga gctgggtgca ggggtggtaa accctggcca 2983
 gacctggagt tcaggagggc cccggggccac cctgaccttt gaggggctgc tgtagcatga 3043
 tgcggggtggc cctggggcact tcgagatggc cagagtcacag cttcccgtgt gtgtggtggg 3103
 cctggggaag tggctggtgg agtcgggagc ttcggggccag gcaaggcttg atcccacagc 3163
 agggagcccc tcacccaggc aggcggccac aggcgggtcc ctctgatcc catccctcct 3223
 ttcccag gga gtg gag gat gcc ttc tac acg ttg gtg cgt gag atc cgg 3272
 Gly Val Glu Asp Ala Phe Tyr Thr Leu Val Arg Glu Ile Arg
 155 160
 cag cac aag ctg cgg aag ctg aac cct cct gat gag agt ggc ccc ggc 3320
 Gln His Lys Leu Arg Lys Leu Asn Pro Pro Asp Glu Ser Gly Pro Gly
 165 170 175 180
 tgc atg agc tgc aag tgt gtg ctc tcc tga cgcaggtgag ggggactccc 3370
 Cys Met Ser Cys Lys Cys Val Leu Ser
 185
 agggcggccg ccacgcccac cggatgaccc cggctccccg cccctgccgg tctctggcc 3430
 tgcggtcagc agcctccctt gtgccccgcc cagcacaagc tcaggacatg gaggtgccgg 3490
 atgcaggaag gaggtgcaga cggaaggagg aggaaggaag gacggaagca aggaaggaag 3550
 gaagggctgc tggagcccag tcaccccggg accgtgggcc gaggtgactg cagaccctcc 3610
 cagggaggct gtgcacagac tgtcttgaac atcccaaagt ccaccggaac cccagccctt 3670
 agtccccctc ccaggcctct gtgggccctt gtcgggcaca gatgggatca cagtaaatta 3730
 ttggatggtc ttgatcttgg ttttcggctg aggggtgggac acggtgcgcg tgtggcctgg 3790
 catgaggtat gtcggaacct caggcctgtc cagccctggg ctctccatag cctttgggag 3850
 ggggaggttg ggagaggccg gtcaggggtc tgggctgtgg tgctctctcc tccgcctgc 3910
 cccagtgtcc acggcttctg gcagagagct ctggacaagc aggcagatca taaggacaga 3970
 gagcttactg tgcttctacc aactaggagg gcgtcctggg cctccagagg gaggtggttt 4030
 caggggttgg ggatctgtgc cgggtggctct ggtctctgct gggagccttc ttggcgggtga 4090
 gaggcatac ctttcctgac ttgctcccag cgtgaaatgc acctgccaag aatggcagac 4150
 atagggaccc cgcctcctgg gccttcacat gccagtttt cttcggctct gtggcctgaa 4210
 gcggtctgtg gaccttgaa gttagggctcc agcaccgact ggcctcagge ctctgcctca 4270
 ttggtggtcg ggtagcggcc agtagggcgt gggagcctgg ccatccctgc ctctggagt 4330
 ggacgaggtt ggcagctggg ccgtctgtc ctgccccact ctccccgcc cctgccctca 4390
 ccctaccctt gccccacgcc tgcctcatgg ctggttgctc ttggagcctg gtagtgtcac 4450

tggctcagcc ttgctgggta tacacaggct ctgccacca ctctgctcca aggggcttgc 4510
cctgccttgg gccaagttct aggtctggcc acagccacag acagctcagt cccctgtgtg 4570
gtcatcctgg cttctgctgg gggccacag cgcccttggg gccctcccc tcccagggcc 4630
cgggttgagg ctgggccagg ccctctggga cggggacttg tgccctgtca gggttcccta 4690
tccctgaggt tgggggagag ctagcagggc atgccgctgg ctggccaggg ctgcagggac 4750
actccccctt ttgtccaggg aataccacac tcgcccttct ctccagcgaa caccacactc 4810
gcccttctct ccaggggacg ccacactccc cttctgttcc aggggacgcc aactcccc 4870
ttctctccag gggacgccac actcgccctt ctctccaggg gacgccacac tcgcccttct 4930
ctccagggga cgccacactc gcccttctgt ccaggggacg ccacactcgc cttctctctc 4990
aggggacgcc aactcgccc ttctctccag gggacgccac actccccctt ctgtccaggg 5050
gacgccacac tcccccttct ctccagggga cgccacactc ccccttctct ccaggggacg 5110
ccacactcgc cttctctctc aggggacgcc aactcccc ttctgtccag gggacgccac 5170
actcgccctt ctctccaggg gacgccacac tcgcccttct ctccagggga cgccacactc 5230
cccccttctct ccaggggacg ccacactccc cttctctctc aggggacgcc aactcccc 5290
ttctgtccag gggacgccac actcgccctt ctctccaggg gacgccacac tcccccttct 5350
ctccagggga cgccacactc ccccttctct ccaggggacg ccacactccc cttctgttcc 5410
aggggacgcc aactcgccc ttctctccag gggacgccac actcgccctt ctctccaggg 5470
gacgccacac tcgcccttct ctccagggga cgccacactt gcccttctgt ccagggaatg 5530
ccacactccc cttctctccc agcagcctcc gactgaccag cttccccatc gatagacttc 5590
ccgaggccag gagccctcta gggctgccgg gtgccaccct ggctccttcc acaccgtgct 5650
ggtcactgcc tgctgggggc gtcagatgca ggtgaccctg tgcaggaggt atctctggac 5710
ctgcctcttg gtcattacgg ggctgggcag ggctgggtat caggggccccg ctggggttgc 5770
agggctgggc ctgtgctgtg gtctgggggt gtccaggaca gacgtggagg ggtcagggcc 5830
cagcaccctt gctccatgct gaactgtggg aagcatccag gtccctgggt ggcttcaaca 5890
ggagttccag cacgggaacc actggacaac ctgggggtgtg tcctgatctg gggacaggcc 5950
agccacaccc cgagtcctag ggactccaga gagcagccca ctgccctggg ctccacggaa 6010
gccccctcat gccgctaggg cttggcctcg gggacagccc agctaggcca gtgtgtggca 6070
ggaccaggcc cccatgtggg agctgacccc ttgggattct ggagctgtgc tgatgggcag 6130
gggagagcca gtcctcccc ttgaggagg gtcttgatgc ctgggggttac ccgcagaggc 6190
ctgggtgccg ggacgctccc cggtttggct gaaaggaaag cagatgtggg cagcttctcc 6250
actgagccca tctggtcttc ccggggctgg gcccataga tctgggtccc tgtgtggccc 6310
ccctggtctg atgccgagga taccctgca aactgccaat ccagaggac aagactggga 6370

agtcacctgca gggagagccc atccccgcac cctgacccac aagagggact cctgctgccc 6430
accaggcatc cctccaggga tcc 6453

<210> 11
<211> 189
<212> PRT
<213> Homo sapiens

<400> 11
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1 5 10 15
Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
20 25 30
Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45
Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
50 55 60
Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80
Val Phe Ala Ile Asn Asn Thr Lys Ser Phe Glu Asp Ile His Gln Tyr
85 90 95
Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
100 105 110
Leu Val Gly Asn Lys Cys Asp Leu Ala Ala Arg Thr Val Glu Ser Arg
115 120 125
Gln Ala Gln Asp Leu Ala Arg Ser Tyr Gly Ile Pro Tyr Ile Glu Thr
130 135 140
Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160
Arg Glu Ile Arg Gln His Lys Leu Arg Lys Leu Asn Pro Pro Asp Glu
165 170 175
Ser Gly Pro Gly Cys Met Ser Cys Lys Cys Val Leu Ser
180 185

<210> 12
<211> 2977
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (130)..(2076)

<300>
<308> X03484/Genbank
<309> 1993-09-12

<400> 12
ccgaatgtga ccgcctcccg ctcctcacc cgccgcgggg aggaggagcg ggcgagaagc 60

```

tgccgccgaa cgacaggacg ttggggcggc ctggctccct caggtttaag aattgtttaa 120
gctgcatca atg gag cac ata cag gga gct tgg aag acg atc agc aat ggt 171
      Met Glu His Ile Gln Gly Ala Trp Lys Thr Ile Ser Asn Gly
        1             5             10

ttt gga ttc aaa gat gcc gtg ttt gat ggc tcc agc tgc atc tct cct 219
Phe Gly Phe Lys Asp Ala Val Phe Asp Gly Ser Ser Cys Ile Ser Pro
  15             20             25             30

aca ata gtt cag cag ttt ggc tat cag cgc cgg gca tca gat gat ggc 267
Thr Ile Val Gln Gln Phe Gly Tyr Gln Arg Arg Ala Ser Asp Asp Gly
              35             40             45

aaa ctc aca gat cct tct aag aca agc aac act atc cgt gtt ttc ttg 315
Lys Leu Thr Asp Pro Ser Lys Thr Ser Asn Thr Ile Arg Val Phe Leu
              50             55             60

ccg aac aag caa aga aca gtg gtc aat gtg cga aat gga atg agc ttg 363
Pro Asn Lys Gln Arg Thr Val Val Asn Val Arg Asn Gly Met Ser Leu
              65             70             75

cat gac tgc ctt atg aaa gca ctc aag gtg agg ggc ctg caa cca gag 411
His Asp Cys Leu Met Lys Ala Leu Lys Val Arg Gly Leu Gln Pro Glu
  80             85             90

tgc tgt gca gtg ttc aga ctt ctc cac gaa cac aaa ggt aaa aaa gca 459
Cys Cys Ala Val Phe Arg Leu Leu His Glu His Lys Gly Lys Lys Ala
  95             100             105             110

cgc tta gat tgg aat act gat gct gcg tct ttg att gga gaa gaa ctt 507
Arg Leu Asp Trp Asn Thr Asp Ala Ala Ser Leu Ile Gly Glu Glu Leu
              115             120             125

caa gta gat ttc ctg gat cat gtt ccc ctc aca aca cac aac ttt gct 555
Gln Val Asp Phe Leu Asp His Val Pro Leu Thr Thr His Asn Phe Ala
              130             135             140

cgg aag acg ttc ctg aag ctt gcc ttc tgt gac atc tgt cag aaa ttc 603
Arg Lys Thr Phe Leu Lys Leu Ala Phe Cys Asp Ile Cys Gln Lys Phe
              145             150             155

ctg ctc aat gga ttt cga tgt cag act tgt ggc tac aaa ttt cat gag 651
Leu Leu Asn Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Glu
  160             165             170

cac tgt agc acc aaa gta cct act atg tgt gtg gac tgg agt aac atc 699
His Cys Ser Thr Lys Val Pro Thr Met Cys Val Asp Trp Ser Asn Ile
  175             180             185             190

aga caa ctc tta ttg ttt cca aat tcc act att ggt gat agt gga gtc 747
Arg Gln Leu Leu Phe Pro Asn Ser Thr Ile Gly Asp Ser Gly Val
              195             200             205

cca gca cta cct tct ttg act atg cgt cgt atg cga gag tct gtt tcc 795
Pro Ala Leu Pro Ser Leu Thr Met Arg Arg Met Arg Glu Ser Val Ser
              210             215             220

agg atg cct gtt agt tct cag cac aga tat tct aca cct cac gcc ttc 843
Arg Met Pro Val Ser Ser Gln His Arg Tyr Ser Thr Pro His Ala Phe
              225             230             235

acc ttt aac acc tcc agt ccc tca tct gaa ggt tcc ctc tcc cag agg 891

```


Thr	Phe	Asn	Thr	Ser	Ser	Pro	Ser	Ser	Glu	Gly	Ser	Leu	Ser	Gln	Arg		
240						245					250						
cag	agg	tcg	aca	tcc	aca	cct	aat	gtc	cac	atg	gtc	agc	acc	acg	ctg	939	
Gln	Arg	Ser	Thr	Ser	Thr	Pro	Asn	Val	His	Met	Val	Ser	Thr	Thr	Leu		
255					260					265					270		
cct	gtg	gac	agc	agg	atg	att	gag	gat	gca	att	cga	agt	cac	agc	gaa	987	
Pro	Val	Asp	Ser	Arg	Met	Ile	Glu	Asp	Ala	Ile	Arg	Ser	His	Ser	Glu		
				275					280					285			
tca	gcc	tca	cct	tca	gcc	ctg	tcc	agt	agc	ccc	aac	aat	ctg	agc	cca	1035	
Ser	Ala	Ser	Pro	Ser	Ala	Leu	Ser	Ser	Ser	Pro	Asn	Asn	Leu	Ser	Pro		
			290					295					300				
aca	ggc	tgg	tca	cag	ccg	aaa	acc	ccc	gtg	cca	gca	caa	aga	gag	cgg	1083	
Thr	Gly	Trp	Ser	Gln	Pro	Lys	Thr	Pro	Val	Pro	Ala	Gln	Arg	Glu	Arg		
		305					310					315					
gca	cca	gta	tct	ggg	acc	cag	gag	aaa	aac	aaa	att	agg	cct	cgt	gga	1131	
Ala	Pro	Val	Ser	Gly	Thr	Gln	Glu	Lys	Asn	Lys	Ile	Arg	Pro	Arg	Gly		
		320				325					330						
cag	aga	gat	tca	agc	tat	tat	tgg	gaa	ata	gaa	gcc	agt	gaa	gtg	atg	1179	
Gln	Arg	Asp	Ser	Ser	Tyr	Tyr	Trp	Glu	Ile	Glu	Ala	Ser	Glu	Val	Met		
335					340					345					350		
ctg	tcc	act	cgg	att	ggg	tca	ggc	tct	ttt	gga	act	gtt	tat	aag	ggg	1227	
Leu	Ser	Thr	Arg	Ile	Gly	Ser	Gly	Ser	Phe	Gly	Thr	Val	Tyr	Lys	Gly		
				355					360					365			
aaa	tgg	cac	gga	gat	gtt	gca	gta	aag	atc	cta	aag	gtt	gtc	gac	cca	1275	
Lys	Trp	His	Gly	Asp	Val	Ala	Val	Lys	Ile	Leu	Lys	Val	Val	Asp	Pro		
			370					375					380				
acc	cca	gag	caa	ttc	cag	gcc	ttc	agg	aat	gag	gtg	gct	gtt	ctg	cgc	1323	
Thr	Pro	Glu	Gln	Phe	Gln	Ala	Phe	Arg	Asn	Glu	Val	Ala	Val	Leu	Arg		
		385					390					395					
aaa	aca	cgg	cat	gtg	aac	att	ctg	ctt	ttc	atg	ggg	tac	atg	aca	aag	1371	
Lys	Thr	Arg	His	Val	Asn	Ile	Leu	Leu	Phe	Met	Gly	Tyr	Met	Thr	Lys		
		400				405					410						
gac	aac	ctg	gca	att	gtg	acc	cag	tgg	tgc	gag	ggc	agc	agc	ctc	tac	1419	
Asp	Asn	Leu	Ala	Ile	Val	Thr	Gln	Trp	Cys	Glu	Gly	Ser	Ser	Leu	Tyr		
		415			420					425					430		
aaa	cac	ctg	cat	gtc	cag	gag	acc	aag	ttt	cag	atg	ttc	cag	cta	att	1467	
Lys	His	Leu	His	Val	Gln	Glu	Thr	Lys	Phe	Gln	Met	Phe	Gln	Leu	Ile		
				435					440					445			
gac	att	gcc	cgg	cag	acg	gct	cag	gga	atg	gac	tat	ttg	cat	gca	aag	1515	
Asp	Ile	Ala	Arg	Gln	Thr	Ala	Gln	Gly	Met	Asp	Tyr	Leu	His	Ala	Lys		
			450					455					460				
aac	atc	atc	cat	aga	gac	atg	aaa	tcc	aac	aat	ata	ttt	ctc	cat	gaa	1563	
Asn	Ile	Ile	His	Arg	Asp	Met	Lys	Ser	Asn	Asn	Ile	Phe	Leu	His	Glu		
			465				470					475					
ggc	tta	aca	gtg	aaa	att	gga	gat	ttt	ggg	ttg	gca	aca	gta	aag	tca	1611	
Gly	Leu	Thr	Val	Lys	Ile	Gly	Asp	Phe	Gly	Leu	Ala	Thr	Val	Lys	Ser		
		480				485					490						

cgc tgg agt ggt tct cag cag gtt gaa caa cct act ggc tct gtc ctc 1659
 Arg Trp Ser Gly Ser Gln Gln Val Glu Gln Pro Thr Gly Ser Val Leu
 495 500 505 510

tgg atg gcc cca gag gtg atc cga atg cag gat aac aac cca ttc agt 1707
 Trp Met Ala Pro Glu Val Ile Arg Met Gln Asp Asn Asn Pro Phe Ser
 515 520 525

ttc cag tcg gat gtc tac tcc tat ggc atc gta ttg tat gaa ctg atg 1755
 Phe Gln Ser Asp Val Tyr Ser Tyr Gly Ile Val Leu Tyr Glu Leu Met
 530 535 540

acg ggg gag ctt cct tat tct cac atc aac aac cga gat cag atc atc 1803
 Thr Gly Glu Leu Pro Tyr Ser His Ile Asn Asn Arg Asp Gln Ile Ile
 545 550 555

ttc atg gtg ggc cga gga tat gcc tcc cca gat ctt agt aag cta tat 1851
 Phe Met Val Gly Arg Gly Ala Ser Pro Asp Leu Ser Lys Leu Tyr
 560 565 570

aag aac tgc ccc aaa gca atg aag agg ctg gta gct gac tgt gtg aag 1899
 Lys Asn Cys Pro Lys Ala Met Lys Arg Leu Val Ala Asp Cys Val Lys
 575 580 585 590

aaagta aag gaa gag agg cct ctt ttt ccc cag atc ctg tct tcc att 1947
 Lys Val Lys Glu Glu Arg Pro Leu Phe Pro Gln Ile Leu Ser Ser Ile
 595 600 605

gag ctg ctc caa cac tct cta ccg aag atc aac cgg agc gct tcc gag 1995
 Glu Leu Leu Gln His Ser Leu Pro Lys Ile Asn Arg Ser Ala Ser Glu
 610 615 620

cca tcc ttg cat cgg gca gcc cac act gag gat atc aat gct tgc acg 2043
 Pro Ser Leu His Arg Ala Ala His Thr Glu Asp Ile Asn Ala Cys Thr
 625 630 635

ctg acc acg tcc ccg agg ctg cct gtc ttc tag ttgactttgc acctgtcttc 2096
 Leu Thr Thr Ser Pro Arg Leu Pro Val Phe
 640 645

aggctgccag gggaggagga gaagccagca ggcaccactt ttctgctccc tttctccaga 2156

ggcagaacac atgttttcag agaagctctg ctaaggacct tctagactgc tcacagggcc 2216

ttaacttcat gttgccttct tttctatccc tttgggccct gggagaagga agccatttgc 2276

agtgctggtg tgtcctgctc cctccccaca ttccccatgc tcaaggccca gccttctgta 2336

gatgcgcaag tggatgttga tggtagtaca aaaagcaggg gccagcccc agctgttggc 2396

tacatgagta tttagaggaa gtaaggtagc aggcagtcca gccctgatgt ggagacacat 2456

gggatttttg aaatcagctt ctggaggaat gcatgtcaca ggcgggactt tcttcagaga 2516

gtggtgcagc gccagacatt ttgcacataa ggcaccaaac agcccaggac tgccgagact 2576

ctggccgccc gaaggagcct gctttggtac tatggaactt ttcttagggg acacgtcctc 2636

ctttcacagc ttctaagggtg tccagtgcac tgggatggtt ttccaggcaa ggcaactcggc 2696

caatccgcat ctcagccctc tcaggagcag tcttccatca tgctgaattt tgtcttccag 2756

gagctgcccc tatggggcgg gccgcagggc cagcctgttt ctctaacaaa caaacaacaa 2816

aacagccttg tttctctagt cacatcatgt gtatacaagg aagccaggaa tacaggtttt 2876
 cttgatgatt tgggttttaa ttttgTTTT attgcacctg acaaaaataca gttatctgat 2936
 ggtccctcaa ttatgttatt ttaataaaat aaattaaatt t 2977

<210> 13
 <211> 648
 <212> PRT
 <213> Homo sapiens

<400> 13

Met Glu His Ile Gln Gly Ala Trp Lys Thr Ile Ser Asn Gly Phe Gly
 1 5 10 15
 Phe Lys Asp Ala Val Phe Asp Gly Ser Ser Cys Ile Ser Pro Thr Ile
 20 25 30
 Val Gln Gln Phe Gly Tyr Gln Arg Arg Ala Ser Asp Asp Gly Lys Leu
 35 40 45
 Thr Asp Pro Ser Lys Thr Ser Asn Thr Ile Arg Val Phe Leu Pro Asn
 50 55 60
 Lys Gln Arg Thr Val Val Asn Val Arg Asn Gly Met Ser Leu His Asp
 65 70 75 80
 Cys Leu Met Lys Ala Leu Lys Val Arg Gly Leu Gln Pro Glu Cys Cys
 85 90 95
 Ala Val Phe Arg Leu Leu His Glu His Lys Gly Lys Lys Ala Arg Leu
 100 105 110
 Asp Trp Asn Thr Asp Ala Ala Ser Leu Ile Gly Glu Glu Leu Gln Val
 115 120 125
 Asp Phe Leu Asp His Val Pro Leu Thr Thr His Asn Phe Ala Arg Lys
 130 135 140
 Thr Phe Leu Lys Leu Ala Phe Cys Asp Ile Cys Gln Lys Phe Leu Leu
 145 150 155 160
 Asn Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Glu His Cys
 165 170 175
 Ser Thr Lys Val Pro Thr Met Cys Val Asp Trp Ser Asn Ile Arg Gln
 180 185 190
 Leu Leu Leu Phe Pro Asn Ser Thr Ile Gly Asp Ser Gly Val Pro Ala
 195 200 205
 Leu Pro Ser Leu Thr Met Arg Arg Met Arg Glu Ser Val Ser Arg Met
 210 215 220
 Pro Val Ser Ser Gln His Arg Tyr Ser Thr Pro His Ala Phe Thr Phe
 225 230 235 240
 Asn Thr Ser Ser Pro Ser Ser Glu Gly Ser Leu Ser Gln Arg Gln Arg
 245 250 255
 Ser Thr Ser Thr Pro Asn Val His Met Val Ser Thr Thr Leu Pro Val
 260 265 270

Asp Ser Arg Met Ile Glu Asp Ala Ile Arg Ser His Ser Glu Ser Ala
 275 280 285
 Ser Pro Ser Ala Leu Ser Ser Ser Pro Asn Asn Leu Ser Pro Thr Gly
 290 295 300
 Trp Ser Gln Pro Lys Thr Pro Val Pro Ala Gln Arg Glu Arg Ala Pro
 305 310 315 320
 Val Ser Gly Thr Gln Glu Lys Asn Lys Ile Arg Pro Arg Gly Gln Arg
 325 330 335
 Asp Ser Ser Tyr Tyr Trp Glu Ile Glu Ala Ser Glu Val Met Leu Ser
 340 345 350
 Thr Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp
 355 360 365
 His Gly Asp Val Ala Val Lys Ile Leu Lys Val Val Asp Pro Thr Pro
 370 375 380
 Glu Gln Phe Gln Ala Phe Arg Asn Glu Val Ala Val Leu Arg Lys Thr
 385 390 395 400
 Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Met Thr Lys Asp Asn
 405 410 415
 Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr Lys His
 420 425 430
 Leu His Val Gln Glu Thr Lys Phe Gln Met Phe Gln Leu Ile Asp Ile
 435 440 445
 Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala Lys Asn Ile
 450 455 460
 Ile His Arg Asp Met Lys Ser Asn Asn Ile Phe Leu His Glu Gly Leu
 465 470 475 480
 Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp
 485 490 495
 Ser Gly Ser Gln Gln Val Glu Gln Pro Thr Gly Ser Val Leu Trp Met
 500 505 510
 Ala Pro Glu Val Ile Arg Met Gln Asp Asn Asn Pro Phe Ser Phe Gln
 515 520 525
 Ser Asp Val Tyr Ser Tyr Gly Ile Val Leu Tyr Glu Leu Met Thr Gly
 530 535 540
 Glu Leu Pro Tyr Ser His Ile Asn Asn Arg Asp Gln Ile Ile Phe Met
 545 550 555 560
 Val Gly Arg Gly Tyr Ala Ser Pro Asp Leu Ser Lys Leu Tyr Lys Asn
 565 570 575
 Cys Pro Lys Ala Met Lys Arg Leu Val Ala Asp Cys Val Lys Lys Val
 580 585 590
 Lys Glu Glu Arg Pro Leu Phe Pro Gln Ile Leu Ser Ser Ile Glu Leu
 595 600 605

Leu Gln His Ser Leu Pro Lys Ile Asn Arg Ser Ala Ser Glu Pro Ser
610 615 620

Leu His Arg Ala Ala His Thr Glu Asp Ile Asn Ala Cys Thr Leu Thr
625 630 635 640

Thr Ser Pro Arg Leu Pro Val Phe
645

<210> 14
<211> 1418
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (19)..(1173)

<300>
<308> L26318/Genbank
<309> 1994-04-25

<400> 14
cattaattgc ttgccatc atg agc aga agc aag cgt gac aac aat ttt tat 51
Met Ser Arg Ser Lys Arg Asp Asn Asn Phe Tyr
1 5 10

agt gta gag att gga gat tct aca ttc aca gtc ctg aaa cga tat cag 99
Ser Val Glu Ile Gly Asp Ser Thr Phe Thr Val Leu Lys Arg Tyr Gln
15 20 25

aat tta aaa cct ata ggc tca gga gct caa gga ata gta tgc gca gct 147
Asn Leu Lys Pro Ile Gly Ser Gly Ala Gln Gly Ile Val Cys Ala Ala
30 35 40

tat gat gcc att ctt gaa aga aat gtt gca atc aag aag cta agc cga 195
Tyr Asp Ala Ile Leu Glu Arg Asn Val Ala Ile Lys Lys Leu Ser Arg
45 50 55

cca ttt cag aat cag act cat gcc aag cgg gcc tac aga gag cta gtt 243
Pro Phe Gln Asn Gln Thr His Ala Lys Arg Ala Tyr Arg Glu Leu Val
60 65 70 75

ctt atg aaa tgt gtt aat cac aaa aat ata att ggc ctt ttg aat gtt 291
Leu Met Lys Cys Val Asn His Lys Asn Ile Ile Gly Leu Leu Asn Val
80 85 90

ttc aca cca cag aaa tcc cta gaa gaa ttt caa gat gtt tac ata gtc 339
Phe Thr Pro Gln Lys Ser Leu Glu Glu Phe Gln Asp Val Tyr Ile Val
95 100 105

atg gag ctc atg gat gca aat ctt tgc caa gtg att cag atg gag cta 387
Met Glu Leu Met Asp Ala Asn Leu Cys Gln Val Ile Gln Met Glu Leu
110 115 120

gat cat gaa aga atg tcc tac ctt ctc tat cag atg ctg tgt gga atc 435
Asp His Glu Arg Met Ser Tyr Leu Leu Tyr Gln Met Leu Cys Gly Ile
125 130 135

aag cac ctt cat tct gct gga att att cat cgg gac tta aag ccc agt 483
Lys His Leu His Ser Ala Gly Ile Ile His Arg Asp Leu Lys Pro Ser
140 145 150 155

aat ata gta gta aaa tct gat tgc act ttg aag att ctt gac ttc ggt	531
Asn Ile Val Val Lys Ser Asp Cys Thr Leu Lys Ile Leu Asp Phe Gly	
160 165 170	
ctg gcc agg act gca gga acg agt ttt atg atg acg cct tat gta gtg	579
Leu Ala Arg Thr Ala Gly Thr Ser Phe Met Met Thr Pro Tyr Val Val	
175 180 185	
act cgc tac tac aga gca ccc gag gtc atc ctt ggc atg ggc tac aag	627
Thr Arg Tyr Tyr Arg Ala Pro Glu Val Ile Leu Gly Met Gly Tyr Lys	
190 195 200	
gaa aac gtg gat tta tgg tct gtg ggg tgc att atg gga gaa atg gtt	675
Glu Asn Val Asp Leu Trp Ser Val Gly Cys Ile Met Gly Glu Met Val	
205 210 215	
tgc cac aaa atc ctc ttt cca gga agg gac tat att gat cag tgg aat	723
Cys His Lys Ile Leu Phe Pro Gly Arg Asp Tyr Ile Asp Gln Trp Asn	
220 225 230 235	
aaa gtt att gaa cag ctt gga aca cca tgt cct gaa ttc atg aag aaa	771
Lys Val Ile Glu Gln Leu Gly Thr Pro Cys Pro Glu Phe Met Lys Lys	
240 245 250	
ctg caa cca aca gta agg act tac gtt gaa aac aga cct aaa tat gct	819
Leu Gln Pro Thr Val Arg Thr Tyr Val Glu Asn Arg Pro Lys Tyr Ala	
255 260 265	
gga tat agc ttt gag aaa ctc ttc cct gat gtc ctt ttc cca gct gac	867
Gly Tyr Ser Phe Glu Lys Leu Phe Pro Asp Val Leu Phe Pro Ala Asp	
270 275 280	
tca gaa cac aac aaa ctt aaa gcc agt cag gca agg gat ttg tta tcc	915
Ser Glu His Asn Lys Leu Lys Ala Ser Gln Ala Arg Asp Leu Leu Ser	
285 290 295	
aaa atg ctg gta ata gat gca tct aaa agg atc tct gta gat gaa gct	963
Lys Met Leu Val Ile Asp Ala Ser Lys Arg Ile Ser Val Asp Glu Ala	
300 305 310 315	
ctc caa cac ccg tac atc aat gtc tgg tat gat cct tct gaa gca gaa	1011
Leu Gln His Pro Tyr Ile Asn Val Trp Tyr Asp Pro Ser Glu Ala Glu	
320 325 330	
gct cca cca cca aag atc cct gac aag cag tta gat gaa agg gaa cac	1059
Ala Pro Pro Pro Lys Ile Pro Asp Lys Gln Leu Asp Glu Arg Glu His	
335 340 345	
aca ata gaa gag tgg aaa gaa ttg ata tat aag gaa gtt atg gac ttg	1107
Thr Ile Glu Glu Trp Lys Glu Leu Ile Tyr Lys Glu Val Met Asp Leu	
350 355 360	
gag gag aga acc aag aat gga gtt ata cgg ggg cag ccc tct cct tta	1155
Glu Glu Arg Thr Lys Asn Gly Val Ile Arg Gly Gln Pro Ser Pro Leu	
365 370 375	
gca cag gtg cag cag tga tcaatggctc tcagcatcca tcatcatcgt	1203
Ala Gln Val Gln Gln	
380 385	
cgctctgtcaa tgatgtgtct tcaatgtcaa cagatccgac tttggcctct gatacagaca	1263
gcagtctaga agcagcagct gggcctctgg gctgctgtag atgactactt gggccatcgg	1323

gggggtgggag ggatggggag tcggttagtc attgatagaa ctactttgaa aacaattcag 1383
 tggctcttatt tttgggtgat ttttcaaaaa atgta 1418

<210> 15
 <211> 384
 <212> PRT
 <213> Homo sapiens

<400> 15
 Met Ser Arg Ser Lys Arg Asp Asn Asn Phe Tyr Ser Val Glu Ile Gly
 1 5 10 15
 Asp Ser Thr Phe Thr Val Leu Lys Arg Tyr Gln Asn Leu Lys Pro Ile
 20 25 30
 Gly Ser Gly Ala Gln Gly Ile Val Cys Ala Ala Tyr Asp Ala Ile Leu
 35 40 45
 Glu Arg Asn Val Ala Ile Lys Lys Leu Ser Arg Pro Phe Gln Asn Gln
 50 55 60
 Thr His Ala Lys Arg Ala Tyr Arg Glu Leu Val Leu Met Lys Cys Val
 65 70 75 80
 Asn His Lys Asn Ile Ile Gly Leu Leu Asn Val Phe Thr Pro Gln Lys
 85 90 95
 Ser Leu Glu Glu Phe Gln Asp Val Tyr Ile Val Met Glu Leu Met Asp
 100 105 110
 Ala Asn Leu Cys Gln Val Ile Gln Met Glu Leu Asp His Glu Arg Met
 115 120 125
 Ser Tyr Leu Leu Tyr Gln Met Leu Cys Gly Ile Lys His Leu His Ser
 130 135 140
 Ala Gly Ile Ile His Arg Asp Leu Lys Pro Ser Asn Ile Val Val Lys
 145 150 155 160
 Ser Asp Cys Thr Leu Lys Ile Leu Asp Phe Gly Leu Ala Arg Thr Ala
 165 170 175
 Gly Thr Ser Phe Met Met Thr Pro Tyr Val Val Thr Arg Tyr Tyr Arg
 180 185 190
 Ala Pro Glu Val Ile Leu Gly Met Gly Tyr Lys Glu Asn Val Asp Leu
 195 200 205
 Trp Ser Val Gly Cys Ile Met Gly Glu Met Val Cys His Lys Ile Leu
 210 215 220
 Phe Pro Gly Arg Asp Tyr Ile Asp Gln Trp Asn Lys Val Ile Glu Gln
 225 230 235 240
 Leu Gly Thr Pro Cys Pro Glu Phe Met Lys Lys Leu Gln Pro Thr Val
 245 250 255
 Arg Thr Tyr Val Glu Asn Arg Pro Lys Tyr Ala Gly Tyr Ser Phe Glu
 260 265 270
 Lys Leu Phe Pro Asp Val Leu Phe Pro Ala Asp Ser Glu His Asn Lys

275	280	285
Leu Lys Ala Ser Gln Ala Arg Asp Leu Leu Ser Lys Met Leu Val Ile		
290	295	300
Asp Ala Ser Lys Arg Ile Ser Val Asp Glu Ala Leu Gln His Pro Tyr		
305	310	315
Ile Asn Val Trp Tyr Asp Pro Ser Glu Ala Glu Ala Pro Pro Pro Lys		
	325	330
Ile Pro Asp Lys Gln Leu Asp Glu Arg Glu His Thr Ile Glu Glu Trp		
	340	345
Lys Glu Leu Ile Tyr Lys Glu Val Met Asp Leu Glu Glu Arg Thr Lys		
	355	360
Asn Gly Val Ile Arg Gly Gln Pro Ser Pro Leu Ala Gln Val Gln Gln		
	370	380

<210> 16
 <211> 1782
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (59)..(1333)

<300>
 <308> L31951/Genbank
 <309> 1994-12-06

<400> 16
 gggcgggcgga gggatctgaa acttgccac ccttcgggat attgcaggac gctgcatc 58
 atg agc gac agt aaa tgt gac agt cag ttt tat agt gtg caa gtg gca 106
 Met Ser Asp Ser Lys Cys Asp Ser Gln Phe Tyr Ser Val Gln Val Ala 15
 1 5 10
 gac tca acc ttc act gtc cta aaa cgt tac cag cag ctg aaa cca att 154
 Asp Ser Thr Phe Thr Val Leu Lys Arg Tyr Gln Gln Leu Lys Pro Ile 30
 20 25
 ggc tct ggg gcc caa ggg att gtt tgt gct gca ttt gat aca gtt ctt 202
 Gly Ser Gly Ala Gln Gly Ile Val Cys Ala Ala Phe Asp Thr Val Leu 45
 35 40
 ggg ata agt gtt gca gtc aag aaa cta agc cgt cct ttt cag aac caa 250
 Gly Ile Ser Val Ala Val Lys Lys Leu Ser Arg Pro Phe Gln Asn Gln 60
 50 55
 act cat gca aag aga gct tat cgt gaa ctt gtc ctc tta aaa tgt gtc 298
 Thr His Ala Lys Arg Ala Tyr Arg Glu Leu Val Leu Leu Lys Cys Val 80
 65 70 75
 aat cat aaa aat ata att agt ttg tta aat gtg ttt aca cca caa aaa 346
 Asn His Lys Asn Ile Ile Ser Leu Leu Asn Val Phe Thr Pro Gln Lys 95
 85 90
 act cta gaa gaa ttt caa gat gtg tat ttg gtt atg gaa tta atg gat 394
 Thr Leu Glu Glu Phe Gln Asp Val Tyr Leu Val Met Glu Leu Met Asp

100	105	110	
gct aac tta tgt cag gtt att cac atg gag ctg gat cat gaa aga atg Ala Asn Leu Cys Gln Val Ile His Met Glu Leu Asp His Glu Arg Met 115 120 125			442
tcc tac ctt ctt tac cag atg ctt tgt ggt att aaa cat ctg cat tca Ser Tyr Leu Leu Tyr Gln Met Leu Cys Gly Ile Lys His Leu His Ser 130 135 140			490
gct ggt ata att cat aga gat ttg aag cct agc aac att gtt gtg aaa Ala Gly Ile Ile His Arg Asp Leu Lys Pro Ser Asn Ile Val Val Lys 145 150 155 160			538
tca gac tgc acc ctg aag atc ctt gac ttt ggc ctg gcc cgg aca gcg Ser Asp Cys Thr Leu Lys Ile Leu Asp Phe Gly Leu Ala Arg Thr Ala 165 170 175			586
tgc act aac ttc atg atg acc cct tac gtg gtg aca cgg tac tac cgg Cys Thr Asn Phe Met Met Thr Pro Tyr Val Val Thr Arg Tyr Tyr Arg 180 185 190			634
gcg ccc gaa gtc atc ctg ggt atg ggc tac aaa gag aac gtt gat atc Ala Pro Glu Val Ile Leu Gly Met Gly Tyr Lys Glu Asn Val Asp Ile 195 200 205			682
tgg tca gtg ggt tgc atc atg gga gag ctg gtg aaa ggt tgt gtg ata Trp Ser Val Gly Cys Ile Met Gly Glu Leu Val Lys Gly Cys Val Ile 210 215 220			730
ttc caa ggc act gac cat att gat cag tgg aat aaa gtt att gag cag Phe Gln Gly Thr Asp His Ile Asp Gln Trp Asn Lys Val Ile Glu Gln 225 230 235 240			778
ctg gga aca cca tca gca gag ttc atg aag aaa ctt cag cca act gtg Leu Gly Thr Pro Ser Ala Glu Phe Met Lys Lys Leu Gln Pro Thr Val 245 250 255			826
agg aat tat gtc gaa aac aga cca aag tat cct gga atc aaa ttt gaa Arg Asn Tyr Val Glu Asn Arg Pro Lys Tyr Pro Gly Ile Lys Phe Glu 260 265 270			874
gaa ctc ttt cca gat tgg ata ttc cca tca gaa tct gag cga gac aaa Glu Leu Phe Pro Asp Trp Ile Phe Pro Ser Glu Ser Glu Arg Asp Lys 275 280 285			922
ata aaa aca agt caa gcc aga gat ctg tta tca aaa atg tta gtg att Ile Lys Thr Ser Gln Ala Arg Asp Leu Leu Ser Lys Met Leu Val Ile 290 295 300			970
gat cct gac aag cgg atc tct gta gac gaa gct ctg cgt cac cca tac Asp Pro Asp Lys Arg Ile Ser Val Asp Glu Ala Leu Arg His Pro Tyr 305 310 315 320			1018
atc act gtt tgg tat gac ccc gcc gaa gca gaa gcc cca cca cct caa Ile Thr Val Trp Tyr Asp Pro Ala Glu Ala Glu Ala Pro Pro Pro Gln 325 330 335			1066
att tat gat gcc cag ttg gaa gaa aga gaa cat gca att gaa gaa tgg Ile Tyr Asp Ala Gln Leu Glu Glu Arg Glu His Ala Ile Glu Glu Trp 340 345 350			1114
aaa gag cta att tac aaa gaa gtc atg gat tgg gaa gaa aga agc aag			1162

Lys Glu Leu Ile Tyr Lys Glu Val Met Asp Trp Glu Glu Arg Ser Lys
 355 360 365
 aat ggt gtt gta aaa gat cag cct tca gat gca gca gta agt agc aac 1210
 Asn Gly Val Val Lys Asp Gln Pro Ser Asp Ala Ala Val Ser Ser Asn
 370 375 380
 gcc act cct tct cag tct tca tcg atc aat gac att tca tcc atg tcc 1258
 Ala Thr Pro Ser Gln Ser Ser Ser Ile Asn Asp Ile Ser Ser Met Ser
 385 390 395 400
 act gag cag acg ctg gcc tca gac aca gac agc agt ctt gat gcc tcg 1306
 Thr Glu Gln Thr Leu Ala Ser Asp Thr Asp Ser Ser Leu Asp Ala Ser
 405 410 415
 acg gga ccc ctt gaa ggc tgt cga tga taggttagaa atagcaaacc 1353
 Thr Gly Pro Leu Glu Gly Cys Arg
 420 425
 tgtcagcatt gaaggaactc tcacctccgt gggcctgaaa tgcttgggag ttgatggaac 1413
 caaatagaaa aactccatgt tctgcatgta agaaacacaa tgccttgccc tattcagacc 1473
 tgataggatt gcctgcttag atgataaaat gaggcagaat atgtctgaag aaaaaaattg 1533
 caagccacac ttctagagat tttgttcaag atcatttcag gtgagcagtt agagtaggtg 1593
 aatttgtttc aaattgtact agtgacagtt tctcatcatc tgtaactggt gagatgtatg 1653
 tgcattgtgac cacaaatgct tgcttggaact tgcccattcta gcactttgga aatcagtatt 1713
 taaatgccaa ataatcttcc aggtagtgtc gcttctgaag ttatctctta atcctcttaa 1773
 gtaatttggt 1782

 <210> 17
 <211> 424
 <212> PRT
 <213> Homo sapiens

 <400> 17
 Met Ser Asp Ser Lys Cys Asp Ser Gln Phe Tyr Ser Val Gln Val Ala
 1 5 10 15
 Asp Ser Thr Phe Thr Val Leu Lys Arg Tyr Gln Gln Leu Lys Pro Ile
 20 25 30
 Gly Ser Gly Ala Gln Gly Ile Val Cys Ala Ala Phe Asp Thr Val Leu
 35 40 45
 Gly Ile Ser Val Ala Val Lys Lys Leu Ser Arg Pro Phe Gln Asn Gln
 50 55 60
 Thr His Ala Lys Arg Ala Tyr Arg Glu Leu Val Leu Leu Lys Cys Val
 65 70 75 80
 Asn His Lys Asn Ile Ile Ser Leu Leu Asn Val Phe Thr Pro Gln Lys
 85 90 95
 Thr Leu Glu Glu Phe Gln Asp Val Tyr Leu Val Met Glu Leu Met Asp
 100 105 110

Ala Asn Leu Cys Gln Val Ile His Met Glu Leu Asp His Glu Arg Met
 115 120 125
 Ser Tyr Leu Leu Tyr Gln Met Leu Cys Gly Ile Lys His Leu His Ser
 130 135 140
 Ala Gly Ile Ile His Arg Asp Leu Lys Pro Ser Asn Ile Val Val Lys
 145 150 155 160
 Ser Asp Cys Thr Leu Lys Ile Leu Asp Phe Gly Leu Ala Arg Thr Ala
 165 170 175
 Cys Thr Asn Phe Met Met Thr Pro Tyr Val Val Thr Arg Tyr Tyr Arg
 180 185 190
 Ala Pro Glu Val Ile Leu Gly Met Gly Tyr Lys Glu Asn Val Asp Ile
 195 200 205
 Trp Ser Val Gly Cys Ile Met Gly Glu Leu Val Lys Gly Cys Val Ile
 210 215 220
 Phe Gln Gly Thr Asp His Ile Asp Gln Trp Asn Lys Val Ile Glu Gln
 225 230 235 240
 Leu Gly Thr Pro Ser Ala Glu Phe Met Lys Lys Leu Gln Pro Thr Val
 245 250 255
 Arg Asn Tyr Val Glu Asn Arg Pro Lys Tyr Pro Gly Ile Lys Phe Glu
 260 265 270
 Glu Leu Phe Pro Asp Trp Ile Phe Pro Ser Glu Ser Glu Arg Asp Lys
 275 280 285
 Ile Lys Thr Ser Gln Ala Arg Asp Leu Leu Ser Lys Met Leu Val Ile
 290 295 300
 Asp Pro Asp Lys Arg Ile Ser Val Asp Glu Ala Leu Arg His Pro Tyr
 305 310 315 320
 Ile Thr Val Trp Tyr Asp Pro Ala Glu Ala Glu Ala Pro Pro Pro Gln
 325 330 335
 Ile Tyr Asp Ala Gln Leu Glu Glu Arg Glu His Ala Ile Glu Glu Trp
 340 345 350
 Lys Glu Leu Ile Tyr Lys Glu Val Met Asp Trp Glu Glu Arg Ser Lys
 355 360 365
 Asn Gly Val Val Lys Asp Gln Pro Ser Asp Ala Ala Val Ser Ser Asn
 370 375 380
 Ala Thr Pro Ser Gln Ser Ser Ser Ile Asn Asp Ile Ser Ser Met Ser
 385 390 395 400
 Thr Glu Gln Thr Leu Ala Ser Asp Thr Asp Ser Ser Leu Asp Ala Ser
 405 410 415
 Thr Gly Pro Leu Glu Gly Cys Arg
 420

<210> 18
 <211> 3834

<212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (117)..(1949)

<300>
 <308> M24736/Genbank
 <309> 1994-11-07

<400> 18
 cctgagacag aggcagcagt gatacccacc tgagagatcc tgtgtttgaa caactgcttc 60
 ccaaaacgga aagtatttca agcctaaacc tttgggtgaa aagaactcct gaagtc atg 119
 Met
 1
 att gct tca cag ttt ctc tca gct ctc act ttg gtg ctt ctc att aaa 167
 Ile Ala Ser Gln Phe Leu Ser Ala Leu Thr Leu Val Leu Leu Ile Lys
 5 10 15
 gag agt gga gcc tgg tct tac aac acc tcc acg gaa gct atg act tat 215
 Glu Ser Gly Ala Trp Ser Tyr Asn Thr Ser Thr Glu Ala Met Thr Tyr
 20 25 30
 gat gag gcc agt gct tat tgt cag caa agg tac aca cac ctg gtt gca 263
 Asp Glu Ala Ser Ala Tyr Cys Gln Gln Arg Tyr Thr His Leu Val Ala
 35 40 45
 att caa aac aaa gaa gag att gag tac cta aac tcc ata ttg agc tat 311
 Ile Gln Asn Lys Glu Glu Ile Glu Tyr Leu Asn Ser Ile Leu Ser Tyr
 50 55 60 65
 tca cca agt tat tac tgg att gga atc aga aaa gtc aac aat gtg tgg 359
 Ser Pro Ser Tyr Tyr Trp Ile Gly Ile Arg Lys Val Asn Asn Val Trp
 70 75 80
 gtc tgg gta gga acc cag aaa cct ctg aca gaa gaa gcc aag aac tgg 407
 Val Trp Val Gly Thr Gln Lys Pro Leu Thr Glu Glu Ala Lys Asn Trp
 85 90 95
 gct cca ggt gaa ccc aac aat agg caa aaa gat gag gac tgc gtg gag 455
 Ala Pro Gly Glu Pro Asn Asn Arg Gln Lys Asp Glu Asp Cys Val Glu
 100 105 110
 atc tac atc aag aga gaa aaa gat gtg ggc atg tgg aat gat gag agg 503
 Ile Tyr Ile Lys Arg Glu Lys Asp Val Gly Met Trp Asn Asp Glu Arg
 115 120 125
 tgc agc aag aag aag ctt gcc cta tgc tac aca gct gcc tgt acc aat 551
 Cys Ser Lys Lys Lys Leu Ala Leu Cys Tyr Thr Ala Ala Cys Thr Asn
 130 135 140 145
 aca tcc tgc agt ggc cac ggt gaa tgt gta gag acc atc aat aat tac 599
 Thr Ser Cys Ser Gly His Gly Glu Cys Val Glu Thr Ile Asn Asn Tyr
 150 155 160
 act tgc aag tgt gac cct ggc ttc agt gga ctc aag tgt gag caa att 647
 Thr Cys Lys Cys Asp Pro Gly Phe Ser Gly Leu Lys Cys Glu Gln Ile
 165 170 175
 gtg aac tgt aca gcc ctg gaa tcc cct gag cat gga agc ctg gtt tgc 695

Val	Asn	Cys	Thr	Ala	Leu	Glu	Ser	Pro	Glu	His	Gly	Ser	Leu	Val	Cys		
	180						185					190					
agt	cac	cca	ctg	gga	aac	ttc	agc	tac	aat	tct	tcc	tgc	tct	atc	agc	743	
Ser	His	Pro	Leu	Gly	Asn	Phe	Ser	Tyr	Asn	Ser	Ser	Cys	Ser	Ile	Ser		
	195				200					205							
tgt	gat	agg	ggt	tac	ctg	cca	agc	agc	atg	gag	acc	atg	cag	tgt	atg	791	
Cys	Asp	Arg	Gly	Tyr	Leu	Pro	Ser	Ser	Met	Glu	Thr	Met	Gln	Cys	Met		
	210				215					220					225		
tcc	tct	gga	gaa	tgg	agt	gct	cct	att	cca	gcc	tgc	aat	gtg	gtt	gag	839	
Ser	Ser	Gly	Glu	Trp	Ser	Ala	Pro	Ile	Pro	Ala	Cys	Asn	Val	Val	Glu		
				230					235					240			
tgt	gat	gct	gtg	aca	aat	cca	gcc	aat	ggg	ttc	gtg	gaa	tgt	ttc	caa	887	
Cys	Asp	Ala	Val	Thr	Asn	Pro	Ala	Asn	Gly	Phe	Val	Glu	Cys	Phe	Gln		
			245					250					255				
aac	cct	gga	agc	ttc	cca	tgg	aac	aca	acc	tgt	aca	ttt	gac	tgt	gaa	935	
Asn	Pro	Gly	Ser	Phe	Pro	Trp	Asn	Thr	Thr	Cys	Thr	Phe	Asp	Cys	Glu		
		260					265					270					
gaa	gga	ttt	gaa	cta	atg	gga	gcc	cag	agc	ctt	cag	tgt	acc	tca	tct	983	
Glu	Gly	Phe	Glu	Leu	Met	Gly	Ala	Gln	Ser	Leu	Gln	Cys	Thr	Ser	Ser		
	275					280					285						
ggg	aat	tgg	gac	aac	gag	aag	cca	acg	tgt	aaa	gct	gtg	aca	tgc	agg	1031	
Gly	Asn	Trp	Asp	Asn	Glu	Lys	Pro	Thr	Cys	Lys	Ala	Val	Thr	Cys	Arg		
	290				295					300					305		
gcc	gtc	cgc	cag	cct	cag	aat	ggc	tct	gtg	agg	tgc	agc	cat	tcc	cct	1079	
Ala	Val	Arg	Gln	Pro	Gln	Asn	Gly	Ser	Val	Arg	Cys	Ser	His	Ser	Pro		
				310					315					320			
gct	gga	gag	ttc	acc	ttc	aaa	tca	tcc	tgc	aac	ttc	acc	tgt	gag	gaa	1127	
Ala	Gly	Glu	Phe	Thr	Phe	Lys	Ser	Ser	Cys	Asn	Phe	Thr	Cys	Glu	Glu		
			325					330					335				
ggc	ttc	atg	ttg	cag	gga	cca	gcc	cag	gtt	gaa	tgc	acc	act	caa	ggg	1175	
Gly	Phe	Met	Leu	Gln	Gly	Pro	Ala	Gln	Val	Glu	Cys	Thr	Thr	Gln	Gly		
		340					345					350					
cag	tgg	aca	cag	caa	atc	cca	gtt	tgt	gaa	gct	ttc	cag	tgc	aca	gcc	1223	
Gln	Trp	Thr	Gln	Gln	Ile	Pro	Val	Cys	Glu	Ala	Phe	Gln	Cys	Thr	Ala		
	355					360					365						
ttg	tcc	aac	ccc	gag	cga	ggc	tac	atg	aat	tgt	ctt	cct	agt	gct	tct	1271	
Leu	Ser	Asn	Pro	Glu	Arg	Gly	Tyr	Met	Asn	Cys	Leu	Pro	Ser	Ala	Ser		
	370				375					380					385		
ggc	agt	ttc	cgt	tat	ggg	tcc	agc	tgt	gag	ttc	tcc	tgt	gag	cag	ggt	1319	
Gly	Ser	Phe	Arg	Tyr	Gly	Ser	Ser	Cys	Glu	Phe	Ser	Cys	Glu	Gln	Gly		
				390					395					400			
ttt	gtg	ttg	aag	gga	tcc	aaa	agg	ctc	caa	tgt	ggc	ccc	aca	ggg	gag	1367	
Phe	Val	Leu	Lys	Gly	Ser	Lys	Arg	Leu	Gln	Cys	Gly	Pro	Thr	Gly	Glu		
			405					410					415				
tgg	gac	aac	gag	aag	ccc	aca	tgt	gaa	gct	gtg	aga	tgc	gat	gct	gtc	1415	
Trp	Asp	Asn	Glu	Lys	Pro	Thr	Cys	Glu	Ala	Val	Arg	Cys	Asp	Ala	Val		
		420					425					430					

cac cag ccc ccg aag ggt ttg gtg agg tgt gct cat tcc cct att gga 1463
 His Gln Pro Pro Lys Gly Leu Val Arg Cys Ala His Ser Pro Ile Gly
 435 440 445

gaa ttc acc tac aag tcc tct tgt gcc ttc agc tgt gag gag gga ttt 1511
 Glu Phe Thr Tyr Lys Ser Ser Cys Ala Phe Ser Cys Glu Glu Gly Phe
 450 455 460 465

gaa tta tat gga tca act caa ctt gag tgc aca tct cag gga caa tgg 1559
 Glu Leu Tyr Gly Ser Thr Gln Leu Glu Cys Thr Ser Gln Gly Gln Trp
 470 475 480

aca gaa gag gtt cct tcc tgc caa gtg gta aaa tgt tca agc ctg gca 1607
 Thr Glu Glu Val Pro Ser Cys Gln Val Val Lys Cys Ser Ser Leu Ala
 485 490 495

gtt ccg gga aag atc aac atg agc tgc agt ggg gag ccc gtg ttt ggc 1655
 Val Pro Gly Lys Ile Asn Met Ser Cys Ser Gly Glu Pro Val Phe Gly
 500 505 510

act gtg tgc aag ttc gcc tgt cct gaa gga tgg acg ctc aat ggc tct 1703
 Thr Val Cys Lys Phe Ala Cys Pro Glu Gly Trp Thr Leu Asn Gly Ser
 515 520 525

gca gct cgg aca tgt gga gcc aca gga cac tgg tct ggc ctg cta cct 1751
 Ala Ala Arg Thr Cys Gly Ala Thr Gly His Trp Ser Gly Leu Leu Pro
 530 535 540 545

acc tgt gaa gct ccc act gag tcc aac att ccc ttg gta gct gga ctt 1799
 Thr Cys Glu Ala Pro Thr Glu Ser Asn Ile Pro Leu Val Ala Gly Leu
 550 555 560

tct gct gct gga ctc tcc ctc ctg aca tta gca cca ttt ctc ctc tgg 1847
 Ser Ala Ala Gly Leu Ser Leu Leu Thr Leu Ala Pro Phe Leu Leu Trp
 565 570 575

ctt cgg aaa tgc tta cgg aaa gca aag aaa ttt gtt cct gcc agc agc 1895
 Leu Arg Lys Cys Leu Arg Lys Ala Lys Lys Phe Val Pro Ala Ser Ser
 580 585 590

tgc caa agc ctt gaa tca gac gga agc tac caa aag cct tct tac atc 1943
 Cys Gln Ser Leu Glu Ser Asp Gly Ser Tyr Gln Lys Pro Ser Tyr Ile
 595 600 605

ctt taa gttcaaaaga atcagaaaca ggtgcatctg gggaactaga gggatacact 1999
 Leu
 610

gaagttaaca gagacagata actctcctcg ggtctctggc ccttcttgcc tactatgcca 2059
 gatgccttta tggttgaaac cgcaacaccc atcaccactt caatagatca aagtccagca 2119
 ggcaaggacg gccttcaact gaaaagactc agtggtccct ttctactct caggatcaag 2179
 aaagtgttgg ctaatgaagg gaaaggatat tttcttccaa gcaaagggtga agagaccaag 2239
 actctgaaat ctgagaattc cttttctaac tctcccttgc tcgctgtaaa atcttggcac 2299
 agaaacacaa tattttgttg ctttctttct tttgcccttc acagtgttgc gacagctgat 2359
 tacacagttg ctgtcataag aatgaataat aattatccag agtttagagg aaaaaaatga 2419
 ctaaaaaatat tataacttaa aaaaatgaca gatgttgaat gccacaggc aaatgcatgg 2479

```

agggttggtta atggtgcaaa tcctactgaa tgctctgtgc gagggttact atgcacaatt 2539
taatcacttt catccctatg ggattcagtg cttcttaaaag agttcttaag gattgtgata 2599
tttttacttg cattgaatat attataatct tccatacttc ttcattcaat acaagtgtgg 2659
tagggactta aaaaacttgt aaatgctgtc aactatgata tggtaaaagt tacttattct 2719
agattacccc ctcattgttt attaacaaat tatgttacat ctgttttaaa tttatttcaa 2779
aaagggaac tattgtcccc tagcaaggca tgatgttaac cagaataaag ttctgagtgt 2839
ttttactaca gttgtttttt gaaaacatgg tagaattgga gagtaaaaac tgaatggaag 2899
gtttgtatat tgtcagatat tttttcagaa atatgtggtt tccacgatga aaaacttcca 2959
tgaggccaaa cgttttgaac taataaaagc ataaatgcaa acacacaaag gtataatttt 3019
atgaatgtct ttgttgaaa agaatacaga aagatggatg tgctttgcat tcctacaaag 3079
atgtttgtca gatgtgatat gtaaacataa ttcttgata ttatggaaga ttttaaattc 3139
acaatagaaa ctcaccatgt aaaagagtca tctggtagat ttttaacgaa tgaagatgtc 3199
taatagttat tccctatttg ttttcttctg tatgttaggg tgctctggaa gagaggaatg 3259
cctgtgtgag caagcattta tgtttattta taagcagatt taacaattcc aaaggaatct 3319
ccagttttca gttgatcact ggcaatgaaa aattctcagt cagtaattgc caaagctgct 3379
ctagccttga ggagtgtgag aatcaaaact ctctacact tccattaact tagcatgtgt 3439
tgaaaaaaaa agtttcagag aagttctggc tgaacactgg caacgacaaa gccaacagtc 3499
aaaacagaga tgtgataagg atcagaacag cagaggttct tttaaagggg cagaaaaact 3559
ctgggaaata agagagaaca actactgtga tcaggctatg tatggaatac agtgttattt 3619
tctttgaaat tgtttaagtg ttgtaaatat ttatgtaaac tgcattagaa attagctgtg 3679
tgaaatacca gtgtggtttg tgtttgagtt ttattgagaa ttttaaatta taacttaaaa 3739
tattttataa tttttaaagt atatatttat ttaagcttat gtcagaccta tttgacataa 3799
cactataaag gttgacaata aatgtgctta tgttt 3834

```

<210> 19

<211> 610

<212> PRT

<213> Homo sapiens

<400> 19

```

Met Ile Ala Ser Gln Phe Leu Ser Ala Leu Thr Leu Val Leu Leu Ile
  1             5             10             15

```

```

Lys Glu Ser Gly Ala Trp Ser Tyr Asn Thr Ser Thr Glu Ala Met Thr
          20             25             30

```

```

Tyr Asp Glu Ala Ser Ala Tyr Cys Gln Gln Arg Tyr Thr His Leu Val
      35             40             45

```

```

Ala Ile Gln Asn Lys Glu Glu Ile Glu Tyr Leu Asn Ser Ile Leu Ser

```

50					55					60					
Tyr 65	Ser	Pro	Ser	Tyr	Tyr 70	Trp	Ile	Gly	Ile	Arg 75	Lys	Val	Asn	Asn	Val 80
Trp	Val	Trp	Val	Gly 85	Thr	Gln	Lys	Pro	Leu 90	Thr	Glu	Glu	Ala	Lys 95	Asn
Trp	Ala	Pro	Gly 100	Glu	Pro	Asn	Asn	Arg 105	Gln	Lys	Asp	Glu	Asp 110	Cys	Val
Glu	Ile	Tyr 115	Ile	Lys	Arg	Glu	Lys 120	Asp	Val	Gly	Met	Trp 125	Asn	Asp	Glu
Arg 130	Cys	Ser	Lys	Lys	Lys	Leu 135	Ala	Leu	Cys	Tyr	Thr 140	Ala	Ala	Cys	Thr
Asn 145	Thr	Ser	Cys	Ser	Gly 150	His	Gly	Glu	Cys	Val 155	Glu	Thr	Ile	Asn	Asn 160
Tyr	Thr	Cys	Lys	Cys 165	Asp	Pro	Gly	Phe	Ser 170	Gly	Leu	Lys	Cys	Glu 175	Gln
Ile	Val	Asn	Cys 180	Thr	Ala	Leu	Glu	Ser 185	Pro	Glu	His	Gly	Ser 190	Leu	Val
Cys	Ser	His 195	Pro	Leu	Gly	Asn	Phe 200	Ser	Tyr	Asn	Ser	Ser 205	Cys	Ser	Ile
Ser 210	Cys	Asp	Arg	Gly	Tyr	Leu 215	Pro	Ser	Ser	Met	Glu 220	Thr	Met	Gln	Cys
Met 225	Ser	Ser	Gly	Glu	Trp 230	Ser	Ala	Pro	Ile	Pro 235	Ala	Cys	Asn	Val	Val 240
Glu	Cys	Asp	Ala	Val 245	Thr	Asn	Pro	Ala	Asn 250	Gly	Phe	Val	Glu	Cys 255	Phe
Gln	Asn	Pro	Gly 260	Ser	Phe	Pro	Trp	Asn 265	Thr	Thr	Cys	Thr	Phe 270	Asp	Cys
Glu	Glu	Gly 275	Phe	Glu	Leu	Met	Gly 280	Ala	Gln	Ser	Leu	Gln 285	Cys	Thr	Ser
Ser 290	Gly	Asn	Trp	Asp	Asn	Glu 295	Lys	Pro	Thr	Cys	Lys 300	Ala	Val	Thr	Cys
Arg 305	Ala	Val	Arg	Gln	Pro 310	Gln	Asn	Gly	Ser	Val 315	Arg	Cys	Ser	His	Ser 320
Pro	Ala	Gly	Glu	Phe 325	Thr	Phe	Lys	Ser	Ser 330	Cys	Asn	Phe	Thr	Cys 335	Glu
Glu	Gly	Phe	Met	Leu	Gln	Gly	Pro	Ala 345	Gln	Val	Glu	Cys	Thr 350	Thr	Gln
Gly	Gln	Trp 355	Thr	Gln	Gln	Ile	Pro 360	Val	Cys	Glu	Ala	Phe 365	Gln	Cys	Thr
Ala 370	Leu	Ser	Asn	Pro	Glu	Arg 375	Gly	Tyr	Met	Asn	Cys 380	Leu	Pro	Ser	Ala
Ser	Gly	Ser	Phe	Arg	Tyr	Gly	Ser	Ser	Cys	Glu	Phe	Ser	Cys	Glu	Gln

385 390 395 400
 Gly Phe Val Leu Lys Gly Ser Lys Arg Leu Gln Cys Gly Pro Thr Gly
 405 410 415
 Glu Trp Asp Asn Glu Lys Pro Thr Cys Glu Ala Val Arg Cys Asp Ala
 420 425 430
 Val His Gln Pro Pro Lys Gly Leu Val Arg Cys Ala His Ser Pro Ile
 435 440 445
 Gly Glu Phe Thr Tyr Lys Ser Ser Cys Ala Phe Ser Cys Glu Glu Gly
 450 455 460
 Phe Glu Leu Tyr Gly Ser Thr Gln Leu Glu Cys Thr Ser Gln Gly Gln
 465 470 475 480
 Trp Thr Glu Glu Val Pro Ser Cys Gln Val Val Lys Cys Ser Ser Leu
 485 490 495
 Ala Val Pro Gly Lys Ile Asn Met Ser Cys Ser Gly Glu Pro Val Phe
 500 505 510
 Gly Thr Val Cys Lys Phe Ala Cys Pro Glu Gly Trp Thr Leu Asn Gly
 515 520 525
 Ser Ala Ala Arg Thr Cys Gly Ala Thr Gly His Trp Ser Gly Leu Leu
 530 535 540
 Pro Thr Cys Glu Ala Pro Thr Glu Ser Asn Ile Pro Leu Val Ala Gly
 545 550 555 560
 Leu Ser Ala Ala Gly Leu Ser Leu Leu Thr Leu Ala Pro Phe Leu Leu
 565 570 575
 Trp Leu Arg Lys Cys Leu Arg Lys Ala Lys Lys Phe Val Pro Ala Ser
 580 585 590
 Ser Cys Gln Ser Leu Glu Ser Asp Gly Ser Tyr Gln Lys Pro Ser Tyr
 595 600 605
 Ile Leu
 610

<210> 20
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 20
 ttgaagtcac gattgcttca cagtt

25

<210> 21
 <211> 26
 <212> DNA
 <213> Artificial Sequence
 <220>

<223> PCR primer
<400> 21
ttctgattct tttgaactta aaggat 26

<210> 22
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 22
cgcgatccg cgtactcaga gtt 23

<210> 23
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 23
cggaattccg ttcagggagg cgt 23

<210> 24
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 24
cttaaatgc ctgggaagat ggtcgt 26

<210> 25
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 25
atcaagcatt agctacactt ttgatt 26

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/28965

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : CO7H 21/04, 21/02; C12Q 1/68; A61K 48/00
US CL : 536/ 23.1, 24.3, 24.31, 24.33, 24.5; 435/6, 91.1; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/ 23.1, 24.3, 24.31, 24.33, 24.5; 435/6, 91.1; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,656,612 A (MONIA et al) 12 August 1997 (12.08.1997), column 17, line 19.	26-33
---		-----
Y		14-18
X	WO 92-22651 A1 (ISIS PHARMACEUTICALS, INC.) 23 December 1992 (23.12.92), page 15, lines 1-8.	26-33
---		-----
Y		14-18
X,P	US 5,877,309 A (MCKAY et al) 02 March 1999 (02.03.99), col. 43.	34-38
---		-----
Y,P		1-3, 9-13, 26-28
A	MIN W. et al TNF Initiates E-selectin Transcription in Human Endothelial Cell Through Parallel TRAF-NF-kB and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 Pathways Journal of Immunology. July 1997, Vol. 159. No. 7, pages 3508-3518, especially page 3515.	1-3, 9-13, 26-28, 34-38
X	US 5,405,941 A (JOHNSON) 11 April 1995 (11.04.95), column 12, lines 18-34.	14-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

15 February 2000 (15.02.2000)

Date of mailing of the international search report

08 MAR 2000

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

George Ellis

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

I. national application No.

PCT/US99/28965

Continuation of B. FIELDS SEARCHED Item 3: USPAT, EPO, JPO, Derwent, Caplus, Registry

search terms: antisense, aptamer, triplex, ribozyme, oligonucleotide, TNF- α , "tumor necrosis factor", cell adhesion, ICAM-1, E-selectin, VCAM-1.